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reamble
primary challenge in the development of clinical practice
uidelines is keeping pace with the stream of new data upon
hich recommendations are based. In an effort to respond
ore quickly to new evidence, the American College of
ardiology/American Heart Association (ACC/AHA)
ask Force on Practice Guidelines has created a new
focused update” process to revise the existing guideline
ecommendations that are affected by evolving data or
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STEMI Focused Update January 15, 2008:210–47pinion. Before the initiation of this focused approach,
eriodic updates and revisions of existing guidelines re-
uired up to 3 years to complete. Now, however, new
vidence will be reviewed in an ongoing fashion to more
fficiently respond to important science and treatment
rends that could have a major impact on patient outcomes
nd quality of care. Evidence will be reviewed at least twice
year, and updates will be initiated on an as needed basis as
uickly as possible, while maintaining the rigorous meth-
dology that the ACC and AHA have developed during
heir more than 20 years of partnership.
These updated guideline recommendations reflect a con-
ensus of expert opinion following a thorough review that
onsisted primarily of late-breaking clinical trials identified
hrough a broad-based vetting process as important to the
elevant patient population and of other new data deemed to
ave an impact on patient care (see Section 1.1 for details on
his focused update). It is important to note that this
ocused update is not intended to represent an update based
n a full literature review from the date of the previous
uideline publication. Specific criteria/considerations for
nclusion of new data include:
Publication in a peer-reviewed journal
Large, randomized, placebo-controlled trial(s)
Nonrandomized data deemed important on the basis of
results that impact current safety and efficacy assumptions
Strengths/weakness of research methodology and findings
Likelihood of additional studies influencing current findings
Impact on current performance measure(s) and/or likeli-
hood of the need to develop new performance measure(s)
Requests and requirements for review and update from
the practice community, key stakeholders, and other
sources free of relationships with industry or other
potential bias
Number of previous trials showing consistent results
Need for consistency with other guidelines or guideline
revisions
In analyzing the data and developing updated recommen-
ations and supporting text, the focused update writing
roup used evidence-based methodologies developed by the
CC/AHA Task Force on Practice Guidelines, which are
escribed elsewhere (1,2).
The schema for class of recommendation and level of
vidence is summarized in Table 1, which also illustrates how
he grading system provides estimates of the size of the
reatment effect and the certainty of the treatment effect. Note
hat a recommendation with Level of Evidence B or C does
ot imply that the recommendation is weak. Many important
linical questions addressed in guidelines do not lend them-
elves to clinical trials. Although randomized trials may not be
vailable, there may be a very clear clinical consensus that a
articular test or therapy is useful and effective. Both the class
f recommendation and level of evidence listed in the focused
pdates are based on consideration of the evidence reviewed in
revious iterations of the guidelines as well as the focused apdate. Of note, the implications of older studies that have
nformed recommendations but have not been repeated in
ontemporary settings are carefully considered.
The ACC/AHA practice guidelines address patient popu-
ations (and health care providers) residing in North America.
s such, drugs that are not currently available in North
merica are discussed in the text without a specific class of
ecommendation. For studies performed in large numbers of
ubjects outside of North America, each writing committee
eviews the potential impact of different practice patterns and
atient populations on the treatment effect and on the relevance to
he ACC/AHA target population to determine whether the
ndings should inform a specific recommendation.
The ACC/AHA practice guidelines are intended to assist
ealth care providers in clinical decision making by describ-
ng a range of generally acceptable approaches for the
iagnosis, management, and prevention of specific diseases
r conditions. The guidelines attempt to define practices
hat meet the needs of most patients in most circumstances.
he ultimate judgment regarding care of a particular patient
ust be made by the health care provider and patient in
ight of all the circumstances presented by that patient.
hus, there are circumstances in which deviations from
hese guidelines may be appropriate. Clinical decision mak-
ng should consider the quality and availability of expertise
n the area where care is provided. These guidelines may be
sed as the basis for regulatory or payer decisions, but the
ltimate goal is quality of care and serving the patient’s best
nterests.
Prescribed courses of treatment in accordance with these
ecommendations are only effective if they are followed by
he patient. Because lack of patient adherence may adversely
ffect treatment outcomes, health care providers should
ake every effort to engage the patient in active participa-
ion with prescribed treatment.
The ACC/AHA Task Force on Practice Guidelines makes
very effort to avoid any actual, potential, or perceived conflict
f interest arising from industry relationships or personal
nterests of a writing committee member. All writing commit-
ee members and peer reviewers were required to provide
isclosure statements of all such relationships pertaining to the
rials and other evidence under consideration (see Appendixes
and 2). Final recommendations were balloted to all writing
ommittee members. Writing committee members with sig-
ificant (greater than $10 000) relevant relationships with
ndustry (RWI) were required to recuse themselves from
oting on that recommendation. Writing committee members
ho did not participate are not listed as authors of this focused
pdate.
With the exception of the recommendations presented here,
he full guidelines remain current. Only the recommendations
rom the affected section(s) of the full guidelines are included in
his focused update. For easy reference, all recommendations
rom any section of guidelines impacted by a change are
resented with a notation as to whether they remain current,
re new, or have been modified. When evidence impacts
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January 15, 2008:210–47 STEMI Focused Updateecommendations in more than 1 set of guidelines, those
uidelines are updated concurrently.
The recommendations in this focused update will be con-
idered current until they are superseded by another focused
pdate or the full-text guidelines are revised. This focused
pdate is published in the January 15, 2008, issue of the Journal
f the American College of Cardiology and the January 15, 2008,
ssue of Circulation as an update to the full-text guidelines and
s also posted on the ACC (www.acc.org) and AHA (www.
mericanheart.org) Web sites. Copies of the focused update are
vailable from both organizations.
Sidney C. Smith, Jr., MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
able 1. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpopu
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may b
CC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when wr
complete thought, such that a recommendation, even if separated and presented apart from
ull intent of the recommendation. It is hoped that this will increase readers’ comprehension ofVice-Chair, ACC/AHA Task Force on Practice Guidelines A. Introduction
.1. Evidence Review
ate-breaking clinical trials presented at the 2005 and 2006
nnual scientific meetings of the ACC, AHA, and European
ociety of Cardiology, as well as selected other data, were
eviewed by the standing guideline writing committee along
ith the parent Task Force and other experts to identify those
rials and other key data that might impact guidelines recom-
endations. On the basis of the criteria/considerations noted
bove, recent trial data and other clinical information were
onsidered important enough to prompt a focused update of
he 2004 ACC/AHA Guidelines for the Management of
atients With ST-Elevation Myocardial Infarction [see Chen
M et al. (3); Chen ZM et al. (4); ASSENT-4 PCI (5);
vidence†
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
y clear clinical consensus that a particular test or therapy is useful or effective. †In 2003, the
commendations. All guideline recommendations have been written in full sentences that express
t of the document (including headings above sets of recommendations), would still convey the
idelines and will allow queries at the individual recommendation level.l of E
lations
at the r
e a ver
iting rentman EM et al. (6); Yusuf S et al. (7); Bhatt DL et al. (8);
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STEMI Focused Update January 15, 2008:210–47abatine MS et al. (9); Bennett JS et al. (10); Smith SC Jr et
l. (11); OAT (12,13) and TOSCA (14)].
When considering the new data for this focused update, the
riting group faced the task of weighing evidence from studies
nrolling large numbers of subjects outside North America.
lthough noting that practice patterns and the rigor applied to
ata collection, as well as the genetic makeup of subjects, might
nfluence the observed magnitude of a treatment effect, the
riting group believed the data were relevant to formulation of
ecommendations for management of ST-elevation myocardial
nfarction (STEMI) in North America. The reasons for this
ecision include that 1) a broad array of management strategies
as represented, including substantial proportions of subjects
ho received some form of reperfusion therapy, 2) concomi-
ant treatments with proven efficacy (e.g., aspirin, beta block-
rs, inhibitors of the renin-angiotensin-aldosterone system,
nd statins) were used in the majority of patients, and 3) it was
onsidered an impractical expectation that the tens of thou-
ands of patients with STEMI needed to meet the estimated
ample size for contemporary clinical trials be enrolled exclu-
ively at North American sites.
To provide clinicians with a comprehensive set of data,
henever possible the exact event rates in various treatment
rms of clinical trials are presented to permit calculation of the
bsolute risk difference (ARD) and number needed to treat
NNT) or harm (NNH); the relative treatment effects are
escribed either as odds ratio (OR), relative risk (RR), or
azard ratio (HR), depending on the format in the original
ublication.
Consult the full-text version or executive summary of the
004 ACC/AHA Guidelines for the Management of Pa-
ients With ST-Elevation Myocardial Infarction (15) for
olicy on clinical areas not covered by the focused update.OX-2 indicates cyclooxygenase-2; IV, intravenous/intravenously; NSAIDs, nonsteroidal anti-inflammatoill be incorporated into future revisions and/or updates of
he full-text guidelines.
.2. Organization of Committee and
elationships With Industry
or this focused update, all members of the 2004 STEMI
riting committee were invited to participate; those who
greed (referred to as the 2007 focused update writing
roup) were required to disclose all RWI relevant to the data
nder consideration (2). Focused update writing group
embers who had no significant relevant RWI wrote the
rst draft of the focused update; the draft was then reviewed
nd revised by the full writing group. Each recommendation
equired a confidential vote by the writing group members
efore external review of the document. Any writing com-
ittee member with a significant (greater than $10 000)
elationship with industry relevant to the recommendation
as recused from voting on that recommendation.
.3. Review and Approval
his document was reviewed by 3 outside reviewers nominated
y the ACC and 3 outside reviewers nominated by the AHA,
s well as 1 reviewer each from the American Academy of
amily Physicians and the Canadian Cardiovascular Society
CCS) and 58 individual content reviewers. All reviewer RWI
nformation was collected and distributed to the writing
ommittee and is published in this document (see Appendix 2
or details).
This document was approved for publication by the
overning bodies of the American College of Cardiology
oundation and the American Heart Association and en-
orsed by the American Academy of Family Physicians andndividual recommendations updated in this focused update the Canadian Cardiovascular Society.
. Analgesia
able 2. Updates to Section 6.3.1.3: Analgesia
2004 STEMI Guideline Recommendation 2007 STEMI Focused Update Recommendation Comments
Class I
orphine sulfate (2 to 4 mg IV with increments of 2 to
8 mg IV repeated at 5- to 15-minute intervals) is the
analgesic of choice for management of pain
associated with STEMI. (Level of Evidence: C)
1. Morphine sulfate (2 to 4 mg IV with increments of 2 to 8 mg IV
repeated at 5- to 15-minute intervals) is the analgesic of
choice for management of pain associated with STEMI. (Level
of Evidence: C)
2004 recommendation
remains current in
2007 Update
2. Patients routinely taking NSAIDs (except for aspirin), both
nonselective as well as COX-2 selective agents, before STEMI
should have those agents discontinued at the time of
presentation with STEMI because of the increased risk of
mortality, reinfarction, hypertension, heart failure, and myocardial
rupture associated with their use. (Level of Evidence: C)
New recommendation
Class III
1. NSAIDs (except for aspirin), both nonselective as well as COX-2
selective agents, should not be administered during
hospitalization for STEMI because of the increased risk of
mortality, reinfarction, hypertension, heart failure, and
myocardial rupture associated with their use. (Level of
Evidence: C)
New recommendationry drugs; and STEMI, ST-elevation myocardial infarction.
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January 15, 2008:210–47 STEMI Focused Updatenalysis of retrospective data (16) has raised a question
bout the potentially adverse effects of morphine in patients
ith unstable angina (UA)/non–ST-elevation myocardial
nfarction (NSTEMI). As a result, the recommendation for
orphine pain relief has been reduced to a Class IIa
ecommendation for that patient population. Use of mor-
hine remains a Class I recommendation for patients with
TEMI, however, because STEMI patients should either
ave received reperfusion or are not candidates for reperfu-
ion, and continuing pain requires relief in either case
Table 2).
Because of the known increased risk of cardiovascular. Beta Blockers
lockers in the setting of fibrinolytic therapy has increased
f
(
G
f
e
(
eased t
ary intenhibitors and other nonsteroidal anti-inflammatory drugs
NSAIDs) (17–19), these drugs should be discontinued
mmediately at the time of STEMI (see 2004 STEMI
uidelines, Section 7.12.5, for additional discussion)
3,15,20,21). A substudy analysis from the ExTRACT
IMI-25 (Enoxaparin and Thrombolysis Reperfusion for
cute Myocardial Infarction Treatment–Thrombolysis in
yocardial Infarction) trial (22) demonstrated an increased
isk of death, reinfarction, heart failure, or shock among
atients who were taking NSAIDs within 7 days of enroll-
ent. Longer-term management considerations and a dis-
ussion of the gradient of risk with the various NSAIDS are
vents among patients taking cyclooxygenase-2 (COX-2) found in Section 7.12.5 of the 2004 STEMI Guidelines (15).he 2004 STEMI Guidelines recommendations (Table 3)
ere based on studies that showed a reduced incidence of
ubsequent reinfarction and recurrent ischemia in patients
eceiving both fibrinolytic therapy and intravenous (IV) beta
lockers. However, uncertainty about the use of IV beta
able 3. Updates to Section 6.3.1.5: Beta Blockers
2004 STEMI Guideline Recommendation 2007 STEM
C
ral beta-blocker therapy should be administered
promptly to those patients without a
contraindication, irrespective of concomitant
fibrinolytic therapy or performance of primary
PCI. (Level of Evidence: A)
1. Oral beta-blocker thera
who do not have any of
a low output state, 3) in
relative contraindication
seconds, second- or thir
airway disease). (Level
atients with early contraindications within the
first 24 hours of STEMI should be reevaluated
for candidacy for beta-blocker therapy as
secondary prevention. (Level of Evidence: C)
2. Patients with early cont
should be reevaluated f
prevention. (Level of Ev
atients with moderate or severe LV failure
should receive beta-blocker therapy as
secondary prevention with a gradual titration
scheme. (Level of Evidence: B)
3. Patients with moderate
therapy as secondary p
Evidence: B)
Cl
t is reasonable to administer IV beta blockers
promptly to STEMI patients without
contraindications, especially if a
tachyarrhythmia or hypertension is present.
(Level of Evidence: B)
1. It is reasonable to adm
to STEMI patients who
following: 1) signs of he
increased risk* for card
to beta blockade (PR in
degree heart block, act
Evidence: B)
C
1. IV beta blockers should
of the following: 1) sign
3) increased risk* for c
contraindications to bet
second- or third-degree
disease). (Level of Evide
Risk factors for cardiogenic shock (the greater the number of risk factors present, the higher the
20 mm Hg, sinus tachycardia greater than 110 bpm or heart rate less than 60 bpm, and incr
IV indicates intravenous; LOE, level of evidence; LV, left ventricular; PCI, percutaneous coronollowing 2 later randomized trials of IV beta blockade
23,24), a post-hoc analysis of the use of atenolol in the
USTO-I (Global Utilization of Streptokinase and TPA
or Occluded Coronary Arteries) trial (25), and a review of
arly beta-blocker therapy in myocardial infarction (MI)
cused Update Recommendation Comments
uld be initiated in the first 24 hours for patients
llowing: 1) signs of heart failure, 2) evidence of
ed risk* for cardiogenic shock, or 4) other
eta blockade (PR interval greater than 0.24
ree heart block, active asthma, or reactive
ence: B)
Modified recommendation
(changed LOE and text)
cations within the first 24 hours of STEMI
didacy for beta-blocker therapy as secondary
: C)
2004 recommendation
remains current in
2007 Update
vere LV failure should receive beta-blocker
ion with a gradual titration scheme. (Level of
2004 recommendation
remains current in
2007 Update
a
an IV beta blocker at the time of presentation
pertensive and who do not have any of the
ilure, 2) evidence of a low output state, 3)
ic shock, or 4) other relative contraindications
greater than 0.24 seconds, second- or third-
hma, or reactive airway disease). (Level of
Modified recommendation
(changed text)
I
e administered to STEMI patients who have any
eart failure, 2) evidence of a low output state,
enic shock, or 4) other relative
kade (PR interval greater than 0.24 seconds,
block, active asthma, or reactive airway
)
New recommendation
developing cardiogenic shock) are age greater than 70 years, systolic blood pressure less than
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he COMMIT/CCS-2 (Clopidogrel and Metoprolol in
yocardial Infarction Trial/Second Chinese Cardiac
tudy) (4) randomized 45 852 patients within 24 hours of
nset of suspected MI to receive metoprolol (up to 3 doses
f 5 mg IV each in the first 15 minutes, followed by 200 mg
rally daily) or matching placebo. Fifteen minutes after the
V doses, a 50-mg tablet of metoprolol or placebo was
dministered orally and repeated every 6 hours during Days
to 1 of hospitalization. From Day 2 onward, 200 mg of
ontrolled-release metoprolol or placebo was administered
rally daily (this is the Food and Drug Administration
FDA]-approved regimen for metoprolol in MI) until
ischarge from the hospital or up to a maximum of 4 weeks
n hospital (in survivors, the mean was 15 days). The 2
respecified co-primary outcomes were the composite of
eath, reinfarction, or cardiac arrest and death from any
ause during the scheduled treatment period.
Neither of the co-primary study end points was signifi-
antly reduced by allocation to metoprolol. For every 1000
atients treated, allocation to metoprolol was associated
ith 5 fewer episodes of reinfarction, 5 fewer episodes of
entricular defibrillation, but 11 more episodes of cardio-
enic shock. The excess of cardiogenic shock was seen
hiefly from Days 0 to 1 after hospitalization, whereas the
eductions in reinfarction and ventricular fibrillation ap-
eared from Day 2 onward.
Allocation to metoprolol produced an average relative
ncrease in cardiogenic shock of 30%, with higher rates for
hose greater than 70 years of age, or with systolic blood
ressure less than 120 mm Hg, or with presenting heart rate
reater than 110 bpm, or with Killip class greater than 1. On
verage across the whole study population, the absolute
eduction in arrhythmia-related deaths and the absolute
ncrease in cardiogenic shock–related deaths were of similar
agnitude. No apparent difference was noted between the 2
reatment groups in the other attributed causes of death,
ither individually or in aggregate. Metoprolol allocation
as associated with significantly more persistent hypoten-
ion and more cases of bradycardia.
Though patients at high or low risk could be identified,
he authors noted that they were not able to identify any
ubgroups in which the benefits clearly outweighed the
isks.
.2. Conclusion
his focused update expands on the concepts introduced in
he 2004 STEMI Guidelines, underscoring the potential
isk of administering IV beta blockers to patients with
evere heart failure or cardiogenic shock. There are several
ircumstances in which it can be useful (Class IIa) to
dminister an IV beta blocker acutely to a STEMI patient STable 3), and these situations are discussed below. It is
easonable to administer IV beta-blocker therapy on Days 0
o 1 of hospitalization for STEMI when hypertension is
resent and the patient is not at an increased risk of
ardiogenic shock on the basis of the risk factors defined
bove. Patients with sinus tachycardia or atrial fibrillation
hould have left ventricular (LV) function rapidly evaluated
efore administration of IV beta blockers (or other negative
notropes, such as non-dihydropyridine calcium channel
lockers). From Day 2 onward, when beneficial effects on
einfarction and ventricular fibrillation are seen, administra-
ion of 200 mg of controlled-release oral metoprolol daily
ppears to be safe in hemodynamically stable patients with
TEMI who are free of contraindications. It is prudent to
nitiate a dose of 50 mg of metoprolol orally every 6 hours,
ransitioning to a dose equivalent to 200 mg per day orally
r the maximum tolerated dose. It should be noted that
ong-term use of oral beta blockers is strongly recommended
Class I, Level of Evidence: A) for secondary prevention in
atients at highest risk, such as those with low ejection
raction, heart failure, or postshock, once they have stabi-
ized, with gradual dose titration (27) (see the 2004 STEMI
uidelines, Sections 7.4.1 and 7.12.7) (15).
The results of the COMMIT-CCS 2 trial raise questions
bout the safety of early use of IV beta blockers, particularly
n high-risk populations, and led the writing group to
eexamine the overall evidence base for beta-blocker ther-
py. The evidence base for this therapy was developed more
han 25 years ago in a treatment environment that differs
rom contemporary practice. Moreover, no study included
n oral beta blocker–only arm. The writing group consen-
us, however, was not to change the classification of the
urrent early oral beta-blocker recommendation but to
estrict it to patients who are not at high risk for compli-
ations. In addition, because of the absence of a study that
pecifically evaluated oral therapy alone, the Level of Evi-
ence has been changed from A to B. Nevertheless, early
within 24 hours) oral beta-blocker therapy remains a Class
recommendation for those patients who are not at high
isk for complications. Whether this change should affect
urrent performance measures is beyond the scope of this
ocument. The findings of potential risk of beta-blocker
herapy in COMMIT emphasize the importance of
ontinually monitoring these patients throughout hospi-
alization for signs and symptoms of complications of
herapy, as noted in other sections of the original
uidelines (Sections 6.3.1.5, 7.4.1, and 7.12.7). Because
f the uncertainty about the benefit of oral beta blockers
arly on (e.g., in COMMIT-CCS 2, Days 0 to 1), the
riting group recommends further research and addi-
ional examination at the time of the next revision to the
TEMI Guidelines.
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ocardia.1. Logistics of Care
egardless of the mode of reperfusion, the overarching concept
s to minimize total ischemic time, which is defined as the time
rom onset of symptoms of STEMI to initiation of reperfusion
herapy. It is increasingly clear that 2 types of hospital systems
rovide reperfusion therapy: those with percutaneous coronary
ntervention (PCI) capability and those without PCI capabil-
ty. When PCI capability is available, the best outcomes are
chieved by offering this strategy 24 hours per day, 7 days per
eek (28). The systems goal should be a first medical contact–
o-balloon time within 90 minutes (Table 4, Figure 1). There
hould be an ongoing program of outcomes analysis and
eriodic case review to identify process-of-care strategies that
ill continually improve time to treatment and facilitate rapid
nd appropriate treatment. A comprehensive effort in this
egard is the AHA Mission Lifeline program, a community-
ased national initiative to improve the quality of care and
utcomes of patients with STEMI by improving health care
ystem readiness and response to STEMI (29). The “Door-
o-Balloon (D2B): An Alliance for Quality” campaign
www.d2balliance.org), launched by the ACC in collaboration
ith many organizations, including the AHA, aims to improve
he timeliness of primary PCI. The goal is to increase the
ercentage of patients who receive timely primary PCI, with an
mphasis on having at least 75% of patients treated within 90
inutes of presentation at the hospital, with a recommenda-
ion for the use of evidence-based strategies to reduce needless
elays (30). The 75% goal was set in recognition that some
atients have clinically relevant non–system-based delays that
o not represent quality-of-care issues. In hospitals without
CI capability, immediate transfer for primary PCI is a
reatment option when the expected door-to-balloon time is
ithin 90 minutes of first medical contact (31,32).
It is important to note that the door-to-balloon goal is a
ystems goal that may not be possible to achieve for an
ndividual patient because of patient variables (uncertainty
bout diagnosis, evaluation and treatment of other life-
hreatening conditions, obtaining informed consent, etc.) that
able 4. Updates to Section 6.3.1.6: Reperfusion
2004 STEMI Guideline Recommendation 2007 S
C
rimary PCI should be performed as quickly as possible
with the goal of a medical contact–to-balloon or
door-to-balloon interval of within 90 minutes. (Level
of Evidence: B)
1. STEMI patients p
treated with prim
(see Figure 1) a
TEMI patients presenting to a facility without the
capability for expert, prompt intervention with
primary PCI within 90 minutes of first medical
contact should undergo fibrinolytic therapy unless
contraindicated. (Level of Evidence: A)
2. STEMI patients p
who cannot be t
90 minutes of fi
with fibrinolytic
as a systems go
(Level of Eviden
CI indicates primary coronary intervention; LOE, level of evidence; and STEMI, ST-elevation myelay the patient’s arrival in the interventional cardiology taboratory or anatomical challenges (issues of arterial, coronary,
r lesion access) that prolong the PCI procedure. In the
bsence of such circumstances, however, reperfusion should be
chieved as soon as possible within this time, and many
ospitals with refined systems are approaching median door-
o-balloon times of 60 to 70 minutes. Discussions about
easurement, particularly with respect to inclusion criteria and
he appropriate time to end measurement, are beyond the
cope of this document and are being considered by groups
hat are focusing on how to improve the alignment between
hat is measured and patient outcomes. The focus on mea-
urement should not displace the emphasis on improving
rocesses that will facilitate more rapid treatment that is
elivered safely and appropriately. This committee continues
o endorse the concept that faster times to reperfusion and
etter systems of care are associated with important reductions
n morbidity and mortality rates in patients with STEMI. An
nderutilized but effective strategy for improving systems of
are for STEMI patients is to expand the use of prehospital
2-lead electrocardiography programs by emergency medical
ystems (EMS) that provide advanced life support (33,34).
The emphasis on primary PCI should not obscure the
mportance of fibrinolytic therapy. Many hospital systems in
orth America do not have the capability of meeting the time
oal for primary PCI (35). Therefore, because of the critical
mportance of time to treatment from onset of symptoms of
TEMI in reducing morbidity and mortality, fibrinolytic
herapy is preferred. In these settings, transfer protocols need to be
n place for arranging rescue PCI when clinically indicated (36).
For fibrinolytic therapy, the system goal is to deliver the
rug within 30 minutes of the time that the patient presents to
he hospital (Table 4). The focus for primary PCI is from first
edical contact because in regionalization strategies, extra time
ay be taken to transport patients to a center that performs the
rocedure. Consequently, it is important to consider the time
rom first medical contact. The writing group does believe that
very effort should be made to reduce the time from first
edical contact to fibrinolytic therapy when that is considered
Focused Update Recommendation Comments
ting to a hospital with PCI capability should be
CI within 90 minutes of first medical contact
tems goal. (Level of Evidence: A)
Modified recommendation
(changed LOE and text)
ting to a hospital without PCI capability and
rred to a PCI center and undergo PCI within
dical contact (see Figure 1) should be treated
y within 30 minutes of hospital presentation
ess fibrinolytic therapy is contraindicated.
Modified recommendation
(changed LOE and text)
l infarction.TEMI
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STEMI Focused Update January 15, 2008:210–47igure 1. Options for Transportation of STEMI Patients and Initial Reperfusion Treatment Goals
eperfusion in patients with STEMI can be accomplished by pharmacological (fibrinolysis) or catheter-based (primary PCI) approaches. The overarching goal is to keep total
schemic time within 120 minutes (ideally within 60 minutes) from symptom onset to initiation of reperfusion treatment. Within this context, the following are goals for the med-
cal system* based on the mode of patient transportation and the capabilities of the receiving hospital:
edical System Goals: EMS Transport (Recommended):
If EMS has fibrinolytic capability and the patient qualifies for therapy, prehospital fibrinolysis should be started within 30 minutes of arrival of EMS on the scene.
If EMS is not capable of administering prehospital fibrinolysis and the patient is transported to a non–PCI-capable hospital, the door-to-needle time should be within 30 minutes
for patients for whom fibrinolysis is indicated.
If EMS is not capable of administering prehospital fibrinolysis and the patient is transported to a PCI-capable hospital, the EMS arrival-to-balloon time should be within 90 minutes.
If EMS takes the patient to a non–PCI-capable hospital, it is appropriate to consider emergency interhospital transfer of the patient to a PCI-capable hospital for mechanical
revascularization if
X There is a contraindication to fibrinolysis.
X PCI can be initiated promptly within 90 minutes from EMS arrival-to-balloon time at the PCI-capable hospital.†
X Fibrinolysis is administered and is unsuccessful (i.e., “rescue PCI”).
atient Self-Transport (Discouraged):
If the patient arrives at a non–PCI-capable hospital, the door-to-needle time should be within 30 minutes of arrival at the emergency department.
If the patient arrives at a PCI-capable hospital, the door-to-balloon time should be within 90 minutes.
If the patient presents to a non–PCI-capable hospital, it is appropriate to consider emergency interhospital transfer of the patient to a PCI-capable hospital if
X There is a contraindication to fibrinolysis.
X PCI can be initiated within 90 minutes after the patient presented to the initial receiving hospital or within 60 minutes compared with when fibrinolysis with a fibrin-specific
agent could be initiated at the initial receiving hospital.
X Fibrinolysis is administered and is unsuccessful (i.e., “rescue PCI”).
The medical system goal is to facilitate rapid recognition and treatment of patients with STEMI so that door-to-needle (or medical contact-to-needle) for initiation of fibrinolytic
herapy can be achieved within 30 minutes or door-to-balloon (or medical contact-to-balloon) for PCI can be achieved within 90 minutes. These goals should not be understood as
ideal” times but rather the longest times that should be considered acceptable for a given system. Systems that are able to achieve even more rapid times for treatment of
atients with STEMI should be encouraged. Note “medical contact” is defined as “time of EMS arrival on scene” after the patient calls EMS/9-1-1 or “time of arrival at the
mergency department door” (whether PCI-capable or non–PCI-capable hospital) when the patient transports himself/herself to the hospital.
EMS Arrival¡Transport to non–PCI-capable hospital¡Arrival at non–PCI-capable hospital to transfer to PCI-capable hospital¡Arrival at PCI-capable hospital-to-balloon time90
inutes.
MS indicates emergency medical system; PCI, percutaneous coronary intervention; and STEMI, ST-elevation myocardial infarction.
odified with permission from (90) and from (15).
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ion myoacilitated PCI refers to a strategy of planned immediate
CI after administration of an initial pharmacological
egimen intended to improve coronary patency before the
rocedure. These regimens have included high-dose hepa-
in, platelet glycoprotein (GP) IIb/IIIa inhibitors, full-dose
r reduced-dose fibrinolytic therapy, and the combination of
GP IIb/IIIa inhibitor with a reduced-dose fibrinolytic
gent (e.g., fibrinolytic dose typically reduced 50%). Facil-
tated PCI should be differentiated from primary PCI
ithout fibrinolytic therapy, from primary PCI with a GP
Ib/IIIa inhibitor started at the time of PCI, from early or
elayed PCI after successful fibrinolytic therapy, and from
escue PCI after unsuccessful fibrinolytic therapy. Potential
dvantages of facilitated PCI include earlier time to reper-
usion, smaller infarct size, improved patient stability, lower
nfarct artery thrombus burden, greater procedural success
ates, higher TIMI (Thrombolysis in Myocardial Infarction
rial) flow rates, and improved survival rates. Potential risks
nclude increased bleeding complications, especially in older
atients. Potential limitations include additional cost (37).
Despite the potential advantages, clinical trials of facili-
ated PCI have not demonstrated any benefit in reducing
nfarct size or improving outcomes. The largest of these was
he ASSENT-4 PCI (Assessment of the Safety and Efficacy
f a New Treatment Strategy with Percutaneous Coronary
ntervention) trial (5), in which 1667 patients were random-
zed to receive full-dose tenecteplase and PCI versus pri-
ary PCI. The trial was terminated prematurely because of
higher in-hospital mortality rate in the facilitated PCI
roup (6% vs. 3%; p0.01). The primary end point, a
omposite of death, shock, and congestive heart failure
ithin 90 days, was significantly higher with facilitated PCI
han with primary PCI (18.6% vs. 13.4%; p0.0045), and
here was a trend toward a higher 90-day mortality rate
6.7% vs. 4.9%; p0.14). Defenders of the facilitated PCI
trategy point out that the absence of an infusion of heparin
fter bolus administration and the absence of a loading dose
f clopidogrel, plus prohibition of GP IIb/IIIa inhibitors
able 5. Updates to Section 6.3.1.6.4.4: Facilitated PCI
2004 STEMI Guideline
Recommendation 2007 STEMI F
Cl
acilitated PCI might be performed as a
reperfusion strategy in higher-risk
patients when PCI is not immediately
available and bleeding risk is low.
(Level of Evidence: B)
1. Facilitated PCI using regimen
considered as a reperfusion s
a. Patients are at high risk, b
minutes, and c. Bleeding risk
hypertension, normal body w
C
1. A planned reperfusion strateg
immediate PCI may be harm
OE indicates level of evidence; PCI, percutaneous coronary intervention, and STEMI, ST-elevatxcept in bail-out situations, made adjunctive antithrom- rotic therapy suboptimal for the facilitated PCI group.
oreover, the median treatment delay between administra-
ion of tenecteplase and PCI was only 104 minutes, and
ortality rates were higher in PCI centers. The evidence on
hether earlier (prehospital) administration of fibrinolytic
herapy, better antithrombotic therapy, longer delays to
CI, or selective use of PCI as a rescue strategy would make
he facilitated PCI strategy beneficial is unclear. These
ssues require further study. On the basis of these data,
owever, facilitated PCI offered no clinical benefit.
Keeley and coworkers performed a quantitative review of
7 trials that compared facilitated PCI with primary PCI
38) (Figure 2). Nine trials involved GP IIb/IIIa inhibitors
lone (n1148), 6 trials with fibrinolytic therapy (including
SSENT-4 PCI) (n2953), and 2 trials with a fibrinolytic
gent plus a GP IIb/IIIa inhibitor (n399). Facilitated PCI
ith fibrinolytic therapy had significantly higher rates of
ortality, nonfatal reinfarction, urgent target-vessel revas-
ularization, total and hemorrhagic stroke, and major bleed-
ng compared with primary PCI. There were no differences
n efficacy or safety when facilitated PCI with a GP IIb/IIIa
nhibitor was compared with primary PCI.
A planned reperfusion strategy using full-dose fibrinolytic
herapy followed by immediate PCI may be harmful (Table
). Nevertheless, selective use of the facilitated strategy with
egimens other than full-dose fibrinolytic therapy in sub-
roups of patients at high risk (large MI or hemodynamic or
lectrical instability) with low risk of bleeding who present
o hospitals without PCI capability might be performed
hen transfer delays for primary PCI are anticipated.
lthough quantitative analysis showed no advantage for
retreatment with a GP IIb/IIIa inhibitor, it did not
ocument any major disadvantage either. The use of GP
Ib/IIIa inhibitors, particularly abciximab, during primary
CI is well established (55). Further trials of reduced-dose
brinolytic therapy, with or without GP IIb/IIIa inhibitors,
re in progress and may yield different efficacy and/or safety
d Update Recommendation Comments
b
r than full-dose fibrinolytic therapy might be
y when all of the following are present:
s not immediately available within 90
(younger age, absence of poorly controlled
(Level of Evidence: C)
Modified recommendation
(changed LOE and text)
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vel of Evidence: B)
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S
nharmacological reperfusion with full-dose fibrinolysis is
ot uniformly successful in restoring antegrade flow in
he infarct artery. In such situations, a strategy of prompt
oronary angiography with intent to perform PCI is
requently contemplated. In certain patients, such as
hose with cardiogenic shock (especially those less than
5 years of age), severe congestive heart failure/
ulmonary edema, or hemodynamically compromising
entricular arrhythmias (regardless of age), a strategy of
able 6. Updates to Section 6.3.1.6.4.5: Immediate (or Emerg
2004 STEMI Guideline Recommendation 2007
C
escue PCI should be performed in patients less than 75
years old with ST elevation or left bundle-branch block
who develop shock within 36 hours of MI and are
suitable for revascularization that can be performed
within 18 hours of shock unless further support is futile
because of the patient’s wishes or contraindications/
unsuitability for further invasive care. (Level of
Evidence: B)
1. A strategy of
emergency C
received fibri
a. Cardiogeni
suitable ca
b. Severe con
(Killip clas
c. Hemodyna
(Level of E
Cl
escue PCI is reasonable for selected patients 75 years
or older with ST elevation or left bundle-branch block or
who develop shock within 36 hours of MI and who are
suitable for revascularization that can be performed
within 18 hours of shock. Patients with good prior
functional status who are suitable for revascularization
and who agree to invasive care may be selected for
such an invasive strategy. (Level of Evidence: B)
1. A strategy of
emergency C
older who ha
cardiogenic s
revasculariza
t is reasonable to perform rescue PCI for patients with 1
or more of the following:
a. Hemodynamic or electrical instability. (Level of
Evidence: C)
b. Persistent ischemic symptoms. (Level of Evidence: C)
2. It is reasonab
more of the f
a. Hemodyna
b. Persistent
3. A strategy of
PCI is reason
failed (ST-seg
minutes follo
showing the
of myocardiu
ventricular in
(Level of Evid
Cl
escue PCI in the absence of 1 or more of the above
Class I or IIa indications is not recommended. (Level of
Evidence: C)
1. A strategy of
the absence
indications m
patients, but
benefits of re
the onset of
C
1. A strategy of
emergency C
received fibri
contraindicat
invasive care
ABG indicates coronary artery bypass graft; COR, class of recommendation; LOE, level of ev
yocardial infarction.oronary angiography with intent to perform PCI is a iseful approach regardless of the time since initiation of
brinolytic therapy, provided further invasive manage-
ent is not considered futile or unsuitable given the
linical circumstances (Table 6). Further discussion of the
anagement of such patients may be found in the 2004
TEMI Guidelines (see Section 6.3.1.6.4.6, as well as
ections 7.6.3 through 7.6.6) (15). These sections have
ot been updated in this document.
In other patients who do not exhibit the clinical instabil-
) Invasive Strategy and Rescue PCI
I Focused Update Recommendation Comments
ary angiography with intent to perform PCI (or
is recommended for patients who have
therapy and have any of the following:
k in patients less than 75 years who are
tes for revascularization (Level of Evidence: B)
e heart failure and/or pulmonary edema
evel of Evidence: B)
y compromising ventricular arrhythmias
e: C)
Modified recommendation
(changed LOE and text)
a
ary angiography with intent to perform PCI (or
is reasonable in patients 75 years of age or
eived fibrinolytic therapy, and are in
provided that they are suitable candidates for
Level of Evidence: B)
Modified recommendation
(changed text)
perform rescue PCI for patients with 1 or
ng:
r electrical instability. (Level of Evidence: C)
ic symptoms. (Level of Evidence: C)
2004 recommendation
remains current in
2007 Update
ary angiography with intent to perform rescue
or patients in whom fibrinolytic therapy has
elevation less than 50% resolved after 90
nitiation of fibrinolytic therapy in the lead
initial elevation) and a moderate or large area
isk (anterior MI, inferior MI with right
ent or precordial ST-segment depression).
B)
New recommendation
b
ary angiography with intent to perform PCI in
or more of the above Class I or IIa
e reasonable in moderate- and high-risk
nefits and risks are not well established. The
CI are greater the earlier it is initiated after
ic discomfort. (Level of Evidence: C)
Modified recommendation
(changed COR from III
to IIb and changed text)
I
ary angiography with intent to perform PCI (or
is not recommended in patients who have
therapy if further invasive management is
the patient or designee does not wish further
l of Evidence: C)
New recommendation
; MI, myocardial infarction; PCI, percutaneous coronary intervention; and STEMI, ST-elevationency
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January 15, 2008:210–47 STEMI Focused Updatelinical suspicion of failure of fibrinolysis. This is referred to
s rescue PCI. Critical to the success of rescue PCI is the
nitial clinical identification of patients who are suspected of
aving failed reperfusion with full-dose fibrinolysis. Because
he presence or absence of ischemic discomfort may be
nreliable for identifying failed reperfusion, clinicians
hould search for evidence of inadequate ST-segment res-
lution on the 12-lead electrocardiogram (ECG). Opera-
ionally, the 12-lead ECG should be scrutinized after
dequate time has elapsed before it is decided that fibrino-
ytic therapy has not been effective. Although earlier times
ave been used in some studies, the writing committee believed
hat 90 minutes after initiation of fibrinolysis was the best time
oint for evaluating the need for rescue PCI; hence, if there is
ess than 50% ST resolution in the lead showing the greatest
egree of ST-segment elevation at presentation, fibrinolytic
herapy has likely failed to produce reperfusion.
The 2004 STEMI Guidelines recommendations for res-
ue PCI were based on observational data and the results of
small randomized clinical trials (n179) from the early
990s (56,57). More recently, MERLIN (Middlesbrough
arly Revascularization to Limit INfarction) (n307),
EACT (Rescue Angioplasty versus Conservative Treat-
ent or Repeat Thrombolysis) (n427), and 3 meta-
nalyses have refocused attention on rescue PCI (58–62).
his subject has been studied with fewer than 1000 patients
igure 2. Short-Term Death in Patients Treated With Facilitate
rials were classified by facilitated regimen. Diamonds and squares indicate odds ranrolled in randomized trials. [In the period between trials studying rescue PCI, there
as a transition between angiographic and electrocardio-
raphic diagnosis to detect failed reperfusion. Importantly,
n the earlier studies, rescue PCI was performed in infarct
rteries with TIMI 0/1 flow, often after a protocol-
andated 90-minute angiogram. In MERLIN and REACT,
owever, patients were randomized if they had less than
0% ST-segment elevation resolution at 60 or 90 min-
tes, respectively. Many patients had patent infarct ar-
eries on angiography; only 54% of patients in MERLIN
nd 74% of patients in REACT (which required less than
IMI grade 3 flow for PCI) actually underwent PCI.
rom a procedural standpoint, stents have replaced bal-
oon angioplasty, antiplatelet therapy has improved with
he addition of a thienopyridine agent and often a GP
Ib/IIIa receptor antagonist, and procedural success rates
re higher.
Despite these historical differences, recent data support
he initial observation that rescue PCI decreases adverse
linical events compared with medical therapy. In the
ijeysundera meta-analysis (62) (Figure 3), there was a
rend toward reduced mortality rates with rescue PCI from
0.4% to 7.3% (RR 0.69 [95% confidence interval (CI) 0.46
o 1.05]; p0.09), reduced reinfarction rates from 10.7% to
.1% (RR 0.58 [95% CI 0.35 to 0.97]; p0.04), and
educed heart failure rates from 17.8% to 12.7% (RR 0.73
Primary PCI
ines indicate 95% confidence intervals. Reprinted with permission from (38).d or
tios. L95% CI 0.54 to 1.00]; p0.05). These event rates suggest
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STEMI Focused Update January 15, 2008:210–47hat high-risk patients were selected for enrollment, so these
ata do not inform the clinical community about the role of
escue PCI in lower-risk patients. Also, the benefits of
escue PCI need to be balanced against the risk. There was
n excess occurrence of stroke in 2 trials (10 events vs. 2
vents), but the majority of the strokes were thromboem-
olic rather than hemorrhagic, and the sample size was
mall, so more data are needed to define this risk. There also
as an increase in absolute risk of bleeding of 13%,
uggesting that adjustments in antithrombotic medication
osing are needed to improve safety. It should be noted that
he majority of patients who underwent rescue PCI received
brinolytic therapy with streptokinase.
Given the association between bleeding events and
ubsequent ischemic events (63), it might be reasonable
o select moderate- and high-risk patients for PCI after
brinolysis and to treat low-risk patients with medical
igure 3. Efficacy End Points for Rescue PCI Versus Conservat
I indicates confidence interval; MERLIN, Middlesbrough Early Revascularization to L
ion; REACT, Rescue Angioplasty versus Conservative Treatment or Repeat Thrombol
anagement of Patients with Early Failure of Thrombolysis for Acute Anterior Myocar
ial Infarction study. Reprinted with permission from (62).herapy. As noted above, patients with cardiogenic shock, cevere heart failure, or hemodynamically compromising
entricular arrhythmias are excellent candidates. An
CG estimate of potential infarct size in patients with
ersistent ST-segment elevation (less than 50% resolu-
ion at 90 minutes following initiation of fibrinolytic
herapy in the lead showing the worst initial evaluation)
nd ongoing ischemic pain is useful for selecting other
atients for rescue PCI. Anterior MI or inferior MI with
ight ventricular involvement or precordial ST-segment
epression usually predicts increased risk (64). Con-
ersely, patients with symptom resolution, improving
T-segment elevation (less than 50% resolution), or
nferior MI localized to 3 ECG leads probably should not
e referred for angiography. Likewise, it is doubtful that
CI of a branch artery (diagonal or obtuse marginal
ranch) will change prognosis in the absence of high-risk
herapy
farction trial; NNT, number needed to treat; PCI, percutaneous coronary interven-
ial; RESCUE, Randomized Comparison of Rescue Angioplasty with Conservative
farction trial; RR, relative risk; and TAMI, Thrombolysis and Angioplasty in Myocar-ive T
imit In
ysis tr
dial Inriteria noted above.
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.s described in the 2004 STEMI Guidelines, PCI has been
erformed immediately after successful fibrinolytic therapy,
ours to days after successful fibrinolytic therapy, and days
o weeks after successful fibrinolytic therapy (15). With the
ncrease in use of an invasive strategy, consideration is now
lso given to PCI in patients who did not undergo fibrino-
ysis, and this concept is reflected in the decision of the
riting committee to rename this section to reflect consid-
rations for PCI both after fibrinolytic therapy and in
TEMI patients who do not undergo primary reperfusion.
ee the 2004 STEMI Guidelines, Section 6.3.1.6, and
pdates herein to Sections 6.3.1.6.4.4 and 6.3.1.6.4.5 for
dditional discussions bearing on PCI after fibrinolysis.
.1. The Late Open Artery Hypothesis:
linical Outcomes
he open artery hypothesis suggested that late patency of an
nfarct artery is associated with improved LV function, in-
reased electrical stability, and provision of collateral vessels to
ther coronary beds for protection against future events. The
AT (Occluded Artery Trial) (12,13) tested the hypothesis
hat routine PCI for total occlusion 3 to 28 days after MI
ould reduce the composite of death, reinfarction, or Class IV
eart failure. Stable patients (n2166) with an occluded
nfarct artery after MI (about 20% of whom received fibrino-
ytic therapy for the index event) were randomized to optimal
edical therapy and PCI with stenting or optimal medical
herapy alone. The qualifying period of 3 to 28 days was based
n calendar days; thus, the minimal time from symptom onset
o angiography was just over 24 hours. Inclusion criteria
ncluded total occlusion of the infarct-related artery with TIMI
rade 0 or 1 antegrade flow and left ventricular ejection fraction
LVEF) less than 50% or proximal occlusion of a major
picardial artery with a large risk region. Exclusion criteria
ncluded NYHA Class III or IV heart failure, rest angina,
erum creatinine greater than 2.5 mg per dL, left main or
-vessel disease, clinical instability, or severe inducible
schemia on stress testing if the infarct zone was not
kinetic or dyskinetic (12). The 4-year cumulative end
able 7. Updates to Section 6.3.1.6.4.7: PCI After Successful
2004 STEMI Guideline Recommendation 2007 STEMI
Cl
outine PCI might be considered as part of
an invasive strategy after fibrinolytic
therapy. (Level of Evidence: B)
1. PCI of a hemodynamically sig
24 hours after STEMI may be
Evidence: B)
C
1. PCI of a totally occluded infar
recommended in asymptoma
hemodynamically and electric
ischemia. (Level of Evidence:
CI indicates percutaneous coronary intervention, and STEMI, ST-elevation myocardial infarctionoint was 17.2% in the PCI group and 15.6% in the cedical therapy group (HR 1.16 [95% CI 0.92 to 1.45];
0.2) (13). Reinfarction rates tended to be higher in the
CI group, which may have attenuated any benefit in LV
emodeling. There was no interaction between treatment
ffect and any subgroup variable.
.2. The Late Open Artery Hypothesis:
ngiographic Outcomes
reclinical studies have suggested that late opening of an
ccluded infarct artery may reduce adverse LV remodeling and
reserve LV volumes. However, 5 previous clinical studies in
63 patients have demonstrated inconsistent improvement in
VEF or LV end-systolic and end-diastolic volumes after
CI. The largest of these, the DECOPI (DEsobstruction
Oronaire en Post-Infarctus) trial, found a higher LVEF at 6
onths with PCI (65). TOSCA-2 (Total Occlusion Study of
anada) (14) enrolled 381 stable patients in a mechanistic
ncillary study of OAT and had the same eligibility criteria
12,13). The PCI procedure success rate was 92% and the
omplication rate was 3%, although 9% had periprocedural MI
s measured by cardiac biomarkers. At 1 year, patency rates
n332) were higher with PCI (83% vs. 25%; p less than
.0001), but each group (n286) had equivalent improvement
n LVEF (4.2% vs. 3.5%; p0.47). There was modest benefit
f PCI in preventing LV dilation over 1 year in a multivariate
odel, but only 42% had paired volume determinations, so it
s unclear whether this finding extends to the whole cohort.
he potential benefit of PCI in attenuating remodeling may
ave been decreased by periprocedural MI and the high rate of
eta blocker and angiotensin-converting enzyme (ACE) in-
ibitor use. There was no significant interaction between
reatment effect and time, infarct artery, or infarct size.
.3. Conclusion
hese studies demonstrate that elective PCI of an occluded
nfarct artery 1 to 28 days after MI in stable patients had no
ncremental benefit beyond optimal medical therapy with
spirin, beta blockers, ACE inhibitors, and statins in pre-
erving LV function and preventing subsequent cardiovas-
nolysis or for Patients Not Undergoing Primary Reperfusion
ed Update Recommendation Comments
b
t stenosis in a patent infarct artery greater than
ered as part of an invasive strategy. (Level of
Modified recommendation
(changed text)
I
ry greater than 24 hours after STEMI is not
ients with one- or two-vessel disease if they are
able and do not have evidence of severe
New recommendationFibri
Focus
ass II
nifican
consid
lass II
ct arte
tic pat
ally st
B)ular events (Table 7).
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004 STEMI Guidelines—Section 6.3.1.6.8.1. Anticoagulants
s Ancillary Therapy to Reperfusion Therapy
Since publication of the 2004 STEMI Guidelines (15), a
umber of studies have provided data that inform the
ecommendations on ancillary therapy to support reperfu-
ion therapy for STEMI. In recognition that many agents
apable of inhibiting the coagulation cascade may inhibit
able 8. Updates to Section 6.3.1.6.8.1: Anticoagulants as An
2004 STEMI
Guideline
ecommendation 2007 STEMI Focused
1. Patients undergoing reperfusion with fibrinolytics shoul
(Level of Evidence: C) and preferably for the duration of
UFH are recommended if anticoagulant therapy is given
induced thrombocytopenia with prolonged UFH treatme
Anticoagulant regimens with established efficacy include:
a. UFH (initial intravenous bolus 60 U per kg [maximum 4
per hour (maximum 1000 U per hour) initially, adjusted
1.5 to 2.0 times control (approximately 50 to 70 secon
suggest a benefit of prolonging the duration of the infu
indications for anticoagulation; more prolonged infusion
induced thrombocytopenia.)
b. Enoxaparin (provided the serum creatinine is less than
patients less than 75 years of age, an initial 30 mg intr
subcutaneous injections of 1.0 mg per kg every 12 hou
intravenous bolus is eliminated and the subcutaneous d
Regardless of age, if the creatinine clearance (using the
estimated to be less than 30 mL per minute, the subcu
Maintenance dosing with enoxaparin should be continu
(Level of Evidence: A)
c. Fondaparinux (provided the serum creatinine is less tha
subsequently subcutaneous injections of 2.5 mg once d
continued for the duration of the index hospitalization,
2. For patients undergoing PCI after having received an an
should be followed:
a. For prior treatment with UFH, administer additional boluelayed-onset presentations) (66,67), the 2004 STEMI
G
r
i
(
U
croteins other than thrombin, the writing group decided to
hange the nomenclature for this section. Therefore, the
erm anticoagulants is used in place of the prior term
ntithrombins. Also, although the material discussed below
rosses several subsections in the 2004 STEMI Guidelines
Sections 6.3.1.6.8.1.1 and 6.3.1.6.8.1.2), because of a
umber of common issues, the writing group has elected to
escribe the updates on anticoagulant therapy collectively in
his section.
ry Therapy to Reperfusion Therapy
e Recommendation Comments
I
ive anticoagulant therapy for a minimum of 48 hours
dex hospitalization, up to 8 days (regimens other than
ore than 48 hours because of the risk of heparin-
evel of Evidence: A)
New recommendatio
]) followed by an intravenous infusion of 12 U per kg
aintain the activated partial thromboplastin time at
vel of Evidence: C). (Note: the available data do not
f UFH beyond 48 hours in the absence of ongoing
FH increase the risk of development of heparin-
g per dL in men and 2.0 mg per dL in women): for
us bolus is given, followed 15 minutes later by
patients at least 75 years of age, the initial
reduced to 0.75 mg per kg every 12 hours.
roft-Gault formula) during the course of treatment is
us regimen is 1.0 mg per kg every 24 hours.
the duration of the index hospitalization, up to 8 days.
mg per dL): initial dose 2.5 mg intravenously;
aintenance dosing with fondaparinux should be
8 days. (Level of Evidence: B)
ulant regimen, the following dosing recommendations New recommendatio
f UFH as needed to support the procedure, taking intonaccount whether GP IIb/IIIa receptor antagonists have been administered. (Level of Evidence: C) Bivalirudin may
also be used in patients treated previously with UFH. (Level of Evidence: C)
b. For prior treatment with enoxaparin, if the last subcutaneous dose was administered within the prior 8 hours, no
additional enoxaparin should be given; if the last subcutaneous dose was administered at least 8 to 12 hours
earlier, an intravenous dose of 0.3 mg per kg of enoxaparin should be given. (Level of Evidence: B)
c. For prior treatment with fondaparinux, administer additional intravenous treatment with an anticoagulant
possessing anti-IIa activity taking into account whether GP IIb/IIIa receptor antagonists have been administered.
(Level of Evidence: C)
Class III
1. Because of the risk of catheter thrombosis, fondaparinux should not be used as the sole anticoagulant to support
PCI. An additional anticoagulant with anti-IIa activity should be administered. (Level of Evidence: C)
New recommendatio
P indicates glycoprotein; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; U, units; and UFH, unfractionated heparin.Unfractionated heparin (UFH) is commonly adminis-
ered to patients receiving fibrinolytic therapy. With limited
vidence supporting the benefits of prolonged infusions of
FH and because of the progressive increase in the risk of
eparin-induced thrombocytopenia (both rapid- anduidelines recommended that infusions of UFH be given
outinely for 48 hours but be given for a longer period only
n patients with an ongoing indication for anticoagulation
15,68,69). Although no new trials specifically focusing on
FH in STEMI were reported, a number of studies havecilla
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January 15, 2008:210–47 STEMI Focused Updatelacebo. Importantly, each study tested a strategy that
nvolved administering the new regimen (reviparin,
ondaparinux, or enoxaparin) for the duration of the index
ospitalization; that is, longer than current practice and
onger than recommended in the 2004 STEMI Guidelines.
n addition, some of the new anticoagulant regimens used
osing schemes that were based on patient weight, age, or
oth. With the exception of reviparin, the details of the
osing schemes are noted in the recommendations above;
he text below refers simply to the name of the anticoagulant
egimen. Major efficacy and safety observations from the
ain trial and important subgroups reported to date are
hown in Table 9.
The CREATE (Cardiovascular risk Reduction by Early
nemia Treatment with Epoetin beta) trial was a random-
zed, double-blind comparison of a strategy of low-
olecular-weight heparin (LMWH) reviparin versus pla-
ebo in 15 570 patients with STEMI enrolled in China and
ndia (70). Although reviparin is not available for clinical
se in North America, the writing group felt that the data
rom the CREATE trial were informative to clinicians and
upported the data from the trials discussed subsequently.
he dosing regimen for reviparin was as follows: for patients
eighing less than 50 kg, subcutaneous injections of 3436
U Ph Eur anti-Xa units every 12 hours; for patients
eighing 50 to 75 kg, subcutaneous injections of 5153 IU
h Eur anti-Xa units every 12 hours; and for patients
eighing more than 75 kg, subcutaneous injections of 6871
U Ph Eur anti-Xa units every 12 hours. Reviparin was
ontinued for the duration of the index hospitalization, up
o 1 week. Fibrinolytic therapy (predominantly non–fibrin-
pecific agents) was administered to 73% of the CREATE
rial population, and it was recommended that the study
rugs be started within 15 minutes of initiation of fibrino-
ysis. A total of 76% of the trial population received blinded
tudy therapy for 7 days (see Table 9).
The OASIS-6 (Organization for the Assessment of
trategies for Ischemic Syndromes) trial was an interna-
ional, randomized, double-blind comparison of fondapa-
inux, a synthetic factor Xa inhibitor, versus control therapy
either placebo or UFH) in 12 092 patients enrolled in 41
ountries (7). Patients for whom the treating physician
hought UFH was not indicated (e.g., non–fibrin-specific
brinolytic administered) were enrolled in stratum I and
eceived placebo in the control arm; patients for whom the
reating physician thought UFH was indicated (e.g., fibrin-
pecific fibrinolytic administered or primary PCI per-
ormed) were enrolled in stratum II and received UFH in
he control arm. The median duration of fondaparinux
herapy was 8 days in stratum I and 7 days in stratum II
compared with 45 hours of UFH). Within the trial
opulation, 2867 patients (23.7%) did not receive any
eperfusion therapy and, depending on physician preference,
ere enrolled in either stratum I or II (see Table 9).
The ExTRACT-TIMI 25 trial was an international,ouble-blind comparison of a strategy of enoxaparin versus aFH in 20 506 patients enrolled in 48 countries who
resented within 6 hours after the onset of STEMI and for
hom fibrinolytic therapy was planned (6). Because prior
rials reported that bleeding with enoxaparin was increased
n elderly patients, a novel dosing regimen was devised for
atients 75 years of age or older, and strict attention was
aid to dose reduction in patients with significantly im-
aired renal function to minimize the accumulation of
nti-Xa activity (71,72). The median duration of treatment
as 7 days with enoxaparin and 2 days for UFH (see Table 9).
Some patients who receive pharmacological reperfusion
ith a fibrinolytic are referred for PCI. Consideration must
e given to the anticoagulant regimen to support PCI in the
ace of preceding (upstream) anticoagulant therapy. The
REATE, OASIS-6, and ExTRACT-TIMI 25 trials took
ifferent approaches to the selection of anticoagulants to
upport PCI. Both CREATE and OASIS-6 included
ubsets of patients undergoing primary PCI; ExTRACT-
IMI 25 did not study patients undergoing primary PCI. In
REATE, patients in both the reviparin and placebo
roups received open-label UFH at the time of PCI. In
ASIS-6, the protocol recommended an IV bolus of
ondaparinux (2.5 to 5.0 mg, depending on whether the
atient received open-label UFH and/or GP IIb/IIIa inhib-
tors before randomization) (see Table 9). The number of
atients in whom catheter thrombosis was observed was 0 in
he UFH group and 22 in the fondaparinux group (p less
han 0.001) (7). When the subset of patients who received
oth open-label UFH and fondaparinux was analyzed, the
umber of catheter thromboses was 0 in the UFH group
nd 2 in the fondaparinux group.
In ExTRACT-TIMI 25, patients were maintained on
he allocated anticoagulant as they moved from the medical
o PCI phase of treatment (n2178) or received open-label
nticoagulant at the treating physician’s discretion if per-
ormed after 8 days (n2498). Among the patients allo-
ated to enoxaparin, a dose of 0.3 mg per kg was adminis-
ered intravenously if the last subcutaneous dose was 8 to 12
ours earlier, whereas no additional enoxaparin was adminis-
ered if the last subcutaneous dose was administered within the
rior 8 hours. UFH was dosed according to the activated
lotting time (ACT), using a target of 200 seconds for patients
eceiving a GP IIb/IIIa inhibitor and 250 seconds for those not
eceiving a GP IIb/IIIa inhibitor (73). The main observations
Table 9) were the same whether the results were analyzed by
ntention to treat or by the actual anticoagulant received during
he procedure (blinded study or open-label anticoagulant if
CI was performed after Day 8) (73).
.1. Conclusion
he writing group felt that several important messages
merged from the CREATE, OASIS-6, and ExTRACT-
IMI 25 trials, and these are reflected in the updated
ecommendations (Table 8) and summarized in Table 10.
nticoagulant therapy is beneficial in patients with STEMI,nd there is benefit in more prolonged anticoagulant ther-
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STEMI Focused Update January 15, 2008:210–47py (duration of index hospitalization) in patients receiving
brinolytics, as seen in the comparisons of reviparin versus
lacebo (CREATE), fondaparinux versus placebo (stratum
in OASIS-6), and enoxaparin versus UFH (ExTRACT-
IMI 25). The mechanism of benefit from a more pro-
onged anticoagulant regimen is probably multifactorial and
ncludes a longer exposure to anticoagulants to prevent
ethrombosis of the infarct artery and prevention of the
ebound increase in events seen after abrupt discontinuation
f UFH infusions. Concern was raised about a rebound
ncrease in events after abrupt discontinuation of UFH
nfusions in patients with UA/NSTEMI (74), but this also
ppears to occur in patients with STEMI (6). The optimum
ethod of terminating treatment with UFH has not been
igorously established for patients with either UA/NSTEMI
r STEMI, but it is common clinical practice to simply
iscontinue UFH infusions. Finally, when the new antico-
gulant regimens are compared with UFH as an active
ontrol, the greater degree of inhibition of the proximal
ortion of the coagulation cascade may lead to a greater
eduction in thrombin generation.
Of note, reviparin, enoxaparin, and fondaparinux all
nvolve, at least in part, clearance via the renal route. Hence,
he potential exists for accumulation of anti-Xa activity with
ncreasing degrees of renal failure. On the basis of available
ata, recommendations have been formulated for baseline
reatinine cut points when a patient is considered for one of
he new regimens. Also, estimation of creatinine clearance
hould be calculated via the Cockcroft-Gault formula rather
han the Modification of Diet and Renal Disease (MDRD)
quation, because the former has been used to modify
osing in clinical trials (75). The writing group endorses
urther research into the optimum anticoagulant regimen in
atients with moderate degrees of renal dysfunction. This
roup has not been studied extensively and may be at an
ncreased risk of bleeding, which has been seen in contem-
orary dosing regimens. The group also recommends head-
o-head comparative studies to evaluate newer anticoagulant
rugs (e.g., fondaparinux, enoxaparin, bivalirudin) to assess
ptimal anticoagulant therapy in patients with STEMI;
uch studies could provide more clinically useful informa-
ion than comparisons against UFH or no anticoagulant.
When added to previous data, the benefits of anticoagu-
ation therapy started concurrently with non–fibrin-specific
brinolytic agents (e.g., streptokinase) seen with all 3 of the
ew anticoagulation regimens led the writing group to
ecommend the use of an anticoagulant across the spectrum
f fibrinolytic agents in common clinical use (6,7,70,76,77).
When moving to PCI after fibrinolytic therapy, those
atients who received upstream UFH or enoxaparin can
ontinue to receive those anticoagulants in a seamless
ashion (i.e., without crossover to another agent) using the
osing regimens listed in the recommendations (73). On the
asis of the reports of catheter thrombosis with fondapa-
inux alone during primary PCI in OASIS-6 and the sxperience with fondaparinux in the OASIS-5 trial (78), the
riting group thought fondaparinux should not be used as
he sole anticoagulant during PCI but should be coupled
ith an additional agent that has anti-IIa activity to
meliorate the risk of catheter complications. Although
ivalirudin and UFH are potential options for supplemental
nticoagulation with fondaparinux, the available experience,
lbeit limited, is largely with UFH. The only available data
rom the CREATE trial that bear on this point are with
FH.
Given the complexities of the characteristics of the
ndividual agents and their actions on the coagulation
ascade, clinicians are cautioned about extrapolating any of
he observations with agents discussed in this update to
ther anticoagulant regimens. In particular, as noted by the
DA, LMWHs are sufficiently distinct that they should be
valuated individually rather than considered as a class of
nterchangeable agents (79).
The writing group also advises clinicians against drawing
omparisons between the new anticoagulant regimens across
rials because of the nonrandomized nature of such com-
arisons and the inability to ensure comparability of baseline
haracteristics for the populations in the trials. Finally, the
riting group strongly cautions clinicians against overinter-
retation of subgroup analyses in the trials listed in Table 9
e.g., reperfusion with either fibrinolytics or PCI versus no
eperfusion; reperfusion with various categories of fibrino-
ytics; and comparison of the new anticoagulant strategy
ersus placebo or UFH). Subgroup comparisons are less
tatistically robust than the main trial results because of their
onrandomized nature, the lack of statistical power to
iscern true differences in treatment effects, and the need to
ccount for multiple comparisons. Nonsignificant interac-
ion tests should not be used to definitively assert a lack of
eterogeneity of treatment effects across subgroups, as such
nalyses are relatively weak statistical tests, especially in the
ase of small sample sizes in subgroups (80–83). In the case
f the data in Table 9, an additional layer of complexity—a
ixture of comparisons between placebo and an active
omparator (UFH)—was introduced. The approach taken
n Table 9 was to provide the point estimate and 95% CI of
he treatment effect in various subgroups to allow readers to
ee the range of possible treatment effects (82).
The writing group encourages randomization of addi-
ional patients in future trials to clarify a number of
uestions, such as 1) the benefits of reviparin compared with
FH in patients receiving fibrin-specific fibrinolytics or
ndergoing PCI, 2) the relative benefits of fondaparinux
ompared with UFH in patients receiving non–fibrin-
pecific and fibrin-specific fibrinolytics, as well as those
atients not undergoing reperfusion, and 3) the relative
enefits of enoxaparin compared with UFH in patients
ndergoing primary PCI and those not receiving reperfu-
ion therapy.
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Trial (Drug) STEMI Cohorts Studied Efficacy Obser
REATE (reviparin) (70)
N  15 570
Fibrinolysis (N  11 355)
Primary PCI (N  949)
No reperfusion (N  3325)
Death/MI/Strok
Reviparin P
N  7780 N
7 d: 9.6% 7
HR 0.87
95% CI 0.79
30 d: 11.8% 3
HR 0.87
95% CI 0.79
Reviparin P
30 d: 11.0% 3
HR 0.90
95% CI 0.81
Reviparin P
30 d: 15.0% 3
HR 0.79
95% CI 0.65
ASIS-6 (fondaparinux
(7,83a,83b)
N  12 092
Fibrinolysis (N  5436)
(Non–fibrin-specific
4561; fibrin-specific
875)
Primary PCI (N  3789)
No reperfusion (N  2867)
Death/MI (D
Fondaparinux C
N  6036 N
9.7% 1
HR 0.86
95% CI 0.77
Fondaparinux P
11.2% 1
HR 0.79
95% CI 0.68
Fondaparinux U
8.3% 8
HR 0.96
95% CI 0.81
Fondaparinux P
10.7% 1
HR 0.76
95% CI 0.64
Fondaparinux U
12.1% 1vations Safety Observations Transition to PCI
e (Day 7) Life-Threatening Bleeds
(Day 7)
Protocol recommended open-
label UFH (54)
lacebo Reviparin Placebo
 7790
d: 11.0% 7 d: 0.9% 7 d: 0.4%
to 0.96
HR 2.49
95% CI 1.61 to 3.87
0 d: 13.6%
to 0.95
Reperfused Cohort
lacebo Reviparin Placebo
0 d: 12.3% 30 d: 1.1% 30 d: 0.4%
to 1.01
HR N/A
Nonreperfused Cohort
lacebo Reviparin Placebo
0 d: 18.3% 30 d: 0.1% 30 d: 0.1%
to 0.95
HR N/A
ay 30) Severe Hemorrhage (Day 9) UFH (guided by ACT) for control
subjects in Stratum II and
supplemental 2.5 to 5.0 mg
IV bolus of fondaparinux
(depending on whether
subject received open-label
UFH and/or GP IIb/IIIa
inhibitors before
randomization) in the
fondaparinux group. Drugs
were administered in
double-blind fashion during
PCI (6).
ontrol Fondaparinux Control
 6056 N  6036 N  6056
1.2% 1.0% 1.3%
to 0.96
HR 0.77
95% CI 0.55 to 1.08
Stratum I
Severe Hemorrhage (Day 9)
lacebo Fondaparinux Placebo
4.0% 1.0% 1.6%
to 0.92
HR 0.63
95% CI 0.40 to 1.02
Stratum II
Severe Hemorrhage (Day 9)
FH Fondaparinux UFH
.7% 1.1% 1.1%
to 1.13
HR 0.95
95% CI 0.59 to 1.52
Non–Fibrin-Specific Lytics
Severe Hemorrhage (Day 30)
lacebo Fondaparinux Placebo
3.8% 1.2% 2.0%
to 0.90
HR 0.60
95% CI 0.37 to 0.97
Fibrin-Specific Lytics
Severe Hemorrhage (Day 30)
FH Fondaparinux UFH
2.1% 1.7% 2.5%
HR 1.01
95% CI 0.69 to 1.48
HR 0.67
95% CI 0.26 to 1.73Continued on next page
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Trial (Drug) STEMI Cohorts Studied Efficacy Observations Safety Observations Transition to PCI
ASIS-6 (Continued) Primary PCI
Severe Hemorrhage (Day 9)
Fondaparinux UFH Fondaparinux UFH
6.1% 5.1% 2.2% 1.7%
HR 1.20
95% CI 0.91 to 1.57
HR 1.30
95% CI 0.81 to 2.08
No Reperfusion
Stratum I Stratum I/Stratum II
Severe Hemorrhage (Day 30)
Fondaparinux Placebo Fondaparinux Control
N  1458 N  1409
12.9% 14.4% 1.5% 2.1%
HR 0.88
95% CI 0.65 to 1.19
HR 0.76
95% CI 0.42 to 1.36
Stratum II
Fondaparinux UFH
11.7% 15.5%
HR 0.74
95% CI 0.57 to 0.97
xTRACT-TIMI 25
(enoxaparin)
N  20 506
(6,73,83c,83d)
Alteplase (N  11 175)
Tenecteplase (N  3986)
Reteplase (N  1122)
Streptokinase (N  4139)
None (N  57)
Death/MI (Day 30) Severe Hemorrhage (Day 30) UFH (guided by ACT) in
subjects allocated to UFH
and supplemental IV bolus
of 0.3 mg per kg enoxaparin
in subjects allocated to
enoxaparin if last
subcutaneous dose was 8 to
12 hours earlier. Drugs
administered in double-blind
fashion during PCI (56,57).
Enoxaparin UFH Enoxaparin UFH
N  10 256 N  10 223 N  10 176 N  10 151
9.9% 12.0% 2.1% 1.4%
RR 0.83
95% CI 0.77 to 0.90
RR 1.53
95% CI 1.23 to 1.89
Age Less Than 75 Years (all lytics)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
7.9% 9.9% 1.9% 1.1%
RR 0.80
95% CI 0.72 to 0.87
RR 1.67
95% CI 1.31 to 2.13
Age 75 Years or Older (all lytics)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
24.8% 26.3% 3.3% 2.9%
RR 0.94
95% CI 0.82 to 1.08
RR 1.15
95% CI 0.74 to 1.78
Fibrin-Specific Lytics (all ages)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
9.8% 12.0% 2.0% 1.2%
OR adj 0.78
95% CI 0.70 to 0.87
RR 1.89
95% CI 1.43 to 2.51Continued on next page
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Trial (Drug) STEMI Cohorts Studied Efficacy Observations Safety Observations Transition to PCI
xTRACT-TIMI 25
(Continued)
Non–Fibrin-Specific Lytics (all ages)
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
10.2% 11.8% 2.4% 2.0%
OR adj 0.83
95% CI 0.66 to 1.04
RR 1.38
95% CI 0.88 to 2.17
PCI postlysis (rescue,
urgent, elective)
N  4676
PCI Postlysis
Severe Hemorrhage (Day 30)
Enoxaparin UFH Enoxaparin UFH
10.7% 13.8% 1.4% 1.6%
RR 0.77
95% CI 0.66 to 0.90
RR 0.87
95% CI 0.55 to 1.39
CT indicates activated clotting time; adj, adjusted; CI, confidence interval; CREATE, Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin Beta; ExTRACT-TIMI 25, Enoxaparin and
hrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction; GP, glycoprotein; HR, hazard ratio; kg, kilogram; MI, myocardial infarction; N, number; N/A,
ot available; OASIS, Organization to Assess Strategies for Ischemic Syndromes; OR, odds ratio; PCI, percutaneous coronary intervention; RR, relative risk; STEMI, ST-elevation myocardial infarction;
nd UFH, unfractionated heparin.able 10. Summary of Observations From Trials of Anticoagulants for STEMI
Anticoagulant Efficacy (through 30 days) Safety Use During PCI
eviparin Fibrinolysis: probably superior to placebo* Increased risk of serious bleeds† No data on reviparin alone during PCI. Additional
anticoagulant with anti-IIa activity, such as UFH or
bivalirudin, recommended.
No reperfusion: probably superior to
placebo*
ondaparinux Fibrinolysis: appears superior to control
therapy (placebo/UFH). Relative benefit
versus placebo and UFH separately
cannot be reliably determined from
available data.*
Trend toward decreased risk of
serious bleeds†
Increased risk of catheter thrombosis when fondaparinux
used alone. Additional anticoagulant with anti-IIa activity,
such as UFH or bivalirudin, recommended.
Primary PCI: when used alone, no
advantage over UFH and trend toward
worse outcome (see “Use During PCI”)
No reperfusion: appears superior to
control therapy (placebo/UFH). Relative
benefit versus placebo and UFH
separately cannot be reliably
determined from available data.*
noxaparin Fibrinolysis: appears superior to UFH Increased risk of serious bleeds† Enoxaparin can be used to support PCI after fibrinolysis.
No additional anticoagulant needed.See text for further discussion and subgroup analysis. †Definitions of significant bleeds varied among trials. Consult original references for details.
PCI indicates percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; and UFH, unfractionated heparin.
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4he 2004 STEMI Guidelines made no specific recommenda-
ion related to dual antiplatelet therapy with clopidogrel plus
ow-dose aspirin for a broad population of patients at high risk
or atherothrombotic events. Clopidogrel has previously been
hown to benefit patients with documented atherosclerosis
recent MI, recent stroke, established peripheral arterial dis-
ase, PCI, and NSTEMI). Since publication of the 2004
TEMI Guidelines, 2 trials have been reported that provide
ata supporting expansion of the use of clopidogrel to the
TEMI end of the acute coronary syndrome spectrum (84).
The COMMIT-CCS-2 study randomized 45 852 pa-
ients within 24 hours of suspected MI at 1250 hospitals in
hina to 75 mg of clopidogrel daily (without a loading
ose) or placebo in addition to 162 mg of aspirin daily (3).
n the trial population, 93% had ST-segment elevation or
undle-branch block, 7% had ST-segment depression, and
4% were treated with fibrinolysis (predominantly uroki-
ase). There was no upper age limit. The mean age was 61
ears; 26% of patients were 70 years of age or older.
wenty-eight percent were women. The study drug treat-
ent was to continue until hospital discharge or up to 4
eeks; mean treatment duration was 14.9 days (25th, 50th,
nd 75th percentiles: 9, 14, and 21 days, respectively). The
omposite primary end point of death, reinfarction, or
troke was reduced from 10.1% in the placebo group to 9.2%
n the clopidogrel group (OR 0.91 [95% CI 0.86 to 0.97];
0.002). Benefit with clopidogrel tended to be seen in the
ubgroups of patients who did and did not receive fibrino-
able 11. Updates to Section 6.3.1.6.8.2.2: Thienopyridines
2004 STEMI Guideline
Recommendation 2007 STEMI Focu
C
1. Clopidogrel 75 mg per day orally shoul
of whether they undergo reperfusion w
therapy. (Level of Evidence: A) Treatme
days. (Level of Evidence: B)
n patients taking clopidogrel
for whom CABG is planned,
the drug should be withheld
for at least 5 days and
preferably for 7 days unless
the urgency for
revascularization outweighs
the risks of excess bleeding.
(Level of Evidence: B)
2. In patients taking clopidogrel in whom
least 5 days and preferably for 7 days u
risks of excess bleeding. (Level of Evide
Cl
1. In patients less than 75 years of age w
reperfusion therapy, it is reasonable to
mg. (Level of Evidence: C) (No data are
loading dose in patients 75 years of ag
2. Long-term maintenance therapy (e.g., 1
reasonable in STEMI patients regardles
therapy or do not receive reperfusion th
ABG indicates coronary artery bypass graft, and STEMI, ST-elevation myocardial infarction.ytic therapy. The co-primary end point of all-cause mor- Tality was reduced from 8.1% in the placebo group to 7.5%
n the clopidogrel group (OR 0.93 [95% CI 0.87 to 0.99];
0.03; NNT167). The rate of cerebral and major
oncerebral bleeding was 0.55% in the placebo group and
.58% in the clopidogrel group (p0.59).
The CLARITY-TIMI 28 (Clopidogrel as Adjunctive
eperfusion Therapy–Thrombolysis in Myocardial Infarc-
ion 28) study randomized 3491 patients (18 to 75 years of
ge) receiving fibrinolytic therapy within 12 hours of
TEMI to clopidogrel (300 mg oral loading dose; 75 mg
ral daily maintenance dose) or placebo (9). The primary
omposite efficacy end point of an occluded infarct artery on
ngiography or death or recurrent MI before angiography
between 48 and 192 hours after the start of study medica-
ion) occurred in 21.7% of the placebo group and 15.0% of
he clopidogrel group (OR 0.64 [95% CI 0.53 to 0.76]; p
ess than 0.001). The benefit of clopidogrel was driven
argely by the reduction in rate of an occluded infarct artery,
hich appears to have been accomplished by preventing
nfarct-related reocclusion rather than by facilitating early
eperfusion (85). The rate of TIMI major bleeding through
0 days was 1.7% in the placebo group and 1.9% in the
lopidogrel group (p0.80). When interpreting the safety
f clopidogrel, especially in the face of a loading dose of 300
g, it is important to note that subjects were excluded from
LARITY-TIMI 28 if they had received more than
000 U of UFH before randomization.
The patients in the clopidogrel arm of CLARITY-
pdate Recommendation Comments
dded to aspirin in patients with STEMI regardless
inolytic therapy or do not receive reperfusion
h clopidogrel should continue for at least 14
New recommendation
is planned, the drug should be withheld for at
the urgency for revascularization outweighs the
)
2004 recommendation
remains current in
2007 Update
a
eive fibrinolytic therapy or who do not receive
ister an oral loading dose of clopidogrel 300
ble to guide decision making regarding an oral
lder.)
New recommendation
with clopidogrel (75 mg per day orally) is
hether they undergo reperfusion with fibrinolytic
. (Level of Evidence: C)
New recommendationsed U
lass I
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nless
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hose in the placebo arm who underwent PCI without
retreatment (86). The composite end point of cardiovas-
ular death, recurrent MI, or stroke from PCI to 30 days
fter enrollment was 6.2% in the non-pretreatment group
nd 3.6% in the pretreatment group (OR 0.54 [95% CI 0.35
o 0.85]; p0.008) (86). There was no significant difference
n the rates of the composite of TIMI major or minor bleeding
n the pretreatment versus non-pretreatment groups (2.0% vs.
.9%; p greater than 0.99).
.1. Conclusion
he writing group felt that the COMMIT-CCS-2 and
LARITY-TIMI 28 trials provided evidence for benefit of
dding clopidogrel to aspirin in patients undergoing fibrino-
ytic therapy (Table 11). The COMMIT-CCS-2 trial also
upported the use of clopidogrel in patients who were not
eceiving reperfusion therapy. Although the available data
uggest that the oral maintenance dose should be 75 mg
aily, uncertainty exists about the efficacy and safety of
dding a loading dose to elderly patients (more than 750. Anticoagulants
r
t
t
d
u
o
c
c
s
b
f
r
(
T-elevahus, the writing group does not recommend a loading dose
n the elderly who receive a fibrinolytic and endorses further
esearch to define the optimum clopidogrel regimen in the
lderly. On the basis of the CLARITY-TIMI 28 study, it
ppears that the administration of clopidogrel at the time of
nitial fibrinolytic therapy is of benefit when PCI is per-
ormed subsequently. No data are available from clinical
rials regarding long-term clopidogrel treatment in STEMI
atients. Extrapolating from experience in patients with
A/NSTEMI, as well as those patients undergoing coro-
ary stenting, the writing committee felt that long-term
herapy with clopidogrel (e.g., 1 year) can be useful in
atients with STEMI (Class IIa; Level of Evidence: C)
Table 11). Clinicians should consult Figure 37 in Section
.12.11 of the 2004 STEMI Guidelines for guidance when
he patient has concurrent indications for oral anticoagula-
ion (15).
In August 2006, the FDA approved the use of clopi-
ogrel for the treatment of patients with STEMI to reduce
he rate of death from any cause and the rate of theears of age), especially when they receive a fibrinolytic. combined end point of death, reinfarction, or stroke (87).n the 2004 STEMI Guidelines, anticoagulant therapy with
FH was recommended for patients not receiving reperfu-
ion with the goal of reducing mortality and reinfarction
ates. In patients with UA/NSTEMI, treatment with
MWH is recommended with a similar goal, as well as for
revention of episodes of recurrent ischemia. Since publi-
ation of the 2004 STEMI Guidelines, 2 trials (CREATE
nd OASIS-6) have extended the database on which such
ecommendations were formulated by providing evidence of
he benefit of anticoagulant therapy in STEMI patients who
o not receive reperfusion therapy (see Tables 9 and 10).
Although 2 contemporary trials provided internally consis-
ent findings of benefit of prolonged anticoagulant therapy
able 12. Updates to Section 7.4.5: Anticoagulants
2004 STEMI Guideline Recommendation 2007
Cl
t is reasonable that STEMI patients who are not undergoing
reperfusion therapy and who do not have a
contraindication to anticoagulation be treated with IV or
subcutaneous UFH or with subcutaneous LMWH for at
least 48 hours. In patients whose clinical condition
necessitates prolonged bedrest and/or minimized
activity, it is reasonable that treatment be continued until
the patient is ambulatory. (Level of Evidence: C)
1. It is reas
undergo
anticoag
of the in
Evidence
include t
fondapa
dosing re
therapy.
V indicates intravenous; LMWH, low-molecular-weight heparin; LOE, level of evidence; STEMI, Seperfusion therapy, the nonreperfusion groups were subgroups
hat represented only about 22% of the trial populations. Also,
he patients were enrolled largely at sites that may have had
ifferent practice patterns than in North America, and there is
ncertainty about the exact magnitude of the treatment effect
f anticoagulants in the absence of more widespread use of
lopidogrel. Because of these issues, the writing group con-
luded that a Class IIa, Level of Evidence: B recommendation
hould be assigned (Table 12). Convenient strategies that may
e used include those with LMWH (Level of Evidence: C) or
ondaparinux (Level of Evidence: B) using the same dosing
egimens as those for patients who receive fibrinolytic therapy
Table 12). See the 2004 STEMI Guidelines, Section 8
I Focused Update Recommendation Comments
a
e for patients with STEMI who do not
usion therapy to be treated with
therapy (non-UFH regimen) for the duration
spitalization, up to 8 days. (Level of
onvenient strategies that can be used
ith LMWH (Level of Evidence: C) or
Level of Evidence: B) using the same
ns as for patients who receive fibrinolytic
ection 6.3.1.6.8.1.
Modified recommendation
(changed LOE and text)
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ehe committee has revised the recommendations for inva-
ive evaluation (Table 13).
2. Secondary Prevention
able 14 contains revised recommendations adapted from the
006 AHA/ACC Guidelines for Secondary Prevention for Pa-
ients with Coronary and Other Atherosclerotic Vascular Disease
11). This table replaces Table 32 from the 2004 STEMI
uidelines (15). Classes of recommendation and a corresponding
evel of evidence have been added for all recommendations. New
ecommendations for clopidogrel have been added to the section
n antiplatelet agents/anticoagulants: clopidogrel 75 mg per day
able 13. Updates to Section 7.11.6: Invasive Evaluation
2004 STEMI Guideline Recommendation 200
Cl
atheterization and revascularization may be considered as part
of a strategy of routine coronary arteriography for risk
assessment after fibrinolytic therapy. (Level of Evidence: B)
1. Coronary
invasive
(Level of
reperfus
OE indicates level of evidence, and STEMI, ST-elevation myocardial infarction.hould be added to aspirin in patients with STEMI for at least 14 mays whether patients undergo reperfusion with fibrinolysis or do
ot receive reperfusion therapy (i.e., all post-PCI nonstented
TEMI patients). The benefits of clopidogrel are likely to con-
inue with longer duration of treatment, although there are no
ata from randomized controlled trials beyond 30 days. This
ection has also been modified slightly to reflect the recent
vidence on aspirin dosage for patients who have undergone PCI
ith stent placement.
Other changes since the 2001 AHA/ACC Secondary
revention Guidelines (88) include the addition of recom-
ended daily physical activity, a recommendation for low-
red low-density lipoprotein cholesterol, and a new recom-
EMI Focused Update Recommendation Comments
b
iography may be considered as part of an
gy for risk assessment after fibrinolytic therapy
nce: B) or for patients not undergoing primary
evel of Evidence: C)
Modified recommendation
(changed LOE and text)7 ST
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2004 STEMI Guideline Recommendations 2007 STEMI Focused Update Recommendations
2007 COR
and LOE Comments
Smoking
2007 Goal: Complete cessation, no exposure to environmental tobacco smoke
ssess tobacco use. 1. Status of tobacco use should be asked about at every visit. I (B) Modified recommendation
(changed text)
trongly encourage patient and family to stop
smoking and to avoid secondhand smoke.
2. Every tobacco user and family members who smoke should be
advised to quit at every visit.
I (B) Modified recommendation
(changed text)
3. The tobacco user’s willingness to quit should be assessed. I (B) New recommendation
rovide counseling, pharmacological therapy
(including nicotine replacement and
bupropion), and formal smoking cessation
programs as appropriate. (See Section
7.12.4 in the 2004 STEMI Guideline for
further discussion.)
4. The tobacco user should be assisted by counseling and developing
a plan for quitting.
I (B) Modified recommendation
(changed text)
5. Follow-up, referral to special programs, or pharmacotherapy
(including nicotine replacement and pharmacological treatment)
should be arranged.
I (B) Modified recommendation
(changed text)
6. Exposure to environmental tobacco smoke at work and home
should be avoided.
I (B) New recommendation
Blood Pressure Control:
2007 Goal: Less than 140/90 mm Hg or less than 130/80 if patient has diabetes or chronic kidney disease
f blood pressure is 120/80 mm Hg or
greater, initiate lifestyle modification
(weight control, physical activity, alcohol
moderation, moderate sodium restriction,
and emphasis on fruits, vegetables, and
low-fat dairy products) in all patients.
1. For patients with blood pressure greater than or equal to 140/90
mm Hg (or greater than or equal to 130/80 mm Hg for patients
with diabetes or chronic kidney disease), it is recommended to
initiate or maintain lifestyle modification—weight control;
increased physical activity; alcohol moderation; sodium reduction;
and emphasis on increased consumption of fresh fruits,
vegetables, and low-fat dairy products.
I (B) Modified recommendation
(changed text)
f blood pressure is 140/90 mm Hg or
greater, or 130/80 mm Hg or greater for
individuals with chronic kidney disease or
diabetes, add blood pressure–reducing
medications,* emphasizing the use of beta
blockers and inhibitors of the renin-
angiotensin-aldosterone system. (See
Sections 7.12.6, 7.12.7, and 7.12.8 in
2004 STEMI Guideline.) (15)
2. For patients with blood pressure greater than or equal to 140/90
mm Hg (or greater than or equal to 130/80 mm Hg for patients
with diabetes or chronic kidney disease), it is useful as tolerated,
to add blood pressure medication, treating initially with beta
blockers and/or ACE inhibitors, with the addition of other drugs
such as thiazides as needed to achieve goal blood pressure.
I (A) Modified recommendation
(changed text)
Lipid Management
2007 Goal: LDL-C substantially less than 100 mg per dL
(If triglycerides are greater than or equal to 200 mg per dL, non–HDL-C should be less than 130 mg per dL†.)
tart dietary therapy in all patients (less than
7% of total calories as saturated fat and
less than 200 mg/d cholesterol).
1. Starting dietary therapy is recommended for all patients. Reduce
intake of saturated fats (to less than 7% of total calories), trans
fatty acids, and cholesterol (to less than 200 mg per day).
I (B) Modified recommendation
(changed text)
2. Adding plant stanol/sterols (2 g per day) and/or viscous fiber
(greater than 10 g per day) is reasonable to further lower LDL-C.
IIa (A) New recommendation
romote physical activity and weight
management.
3. Promotion of daily physical activity and weight management is
recommended.
I (B) Modified recommendation
(changed text)
ncourage increased consumption of omega-
3 fatty acids.
4. It may be reasonable to encourage increased consumption of
omega-3 fatty acids in the form of fish‡ or in capsules (1 g per
day) for risk reduction. For treatment of elevated triglycerides,
higher doses are usually necessary for risk reduction.
IIb (B) Modified recommendation
(changed text)
ssess fasting lipid profile in all patients,
preferably within 24 h of STEMI. Add drug
therapy according to the following guide.
(See Section 7.12.2 in the STEMI 2004
Guideline.)
5. A fasting lipid profile should be assessed in all patients and within
24 hours of hospitalization for those with an acute cardiovascular
or coronary event. For hospitalized patients, initiation of lipid-
lowering medication is indicated as recommended below before
discharge according to the following schedule:
I (A) Modified recommendation
(changed text)
DL-C less than 100 mg/dL (baseline or on
treatment), statins should be used to lower
LDL-C.
● LDL-C should be less than 100 mg per dL. I (A) Modified recommendation
(changed text)
● Further reduction of LDL-C to less than 70 mg per dL is
reasonable.
IIa (A) New recommendation
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2004 STEMI Recommendations 2007 STEMI Recommendations
2007 COR
and LOE Comments
DL-C greater than or equal to 100 mg/dL
(baseline or on treatment), intensify LDL-C-
lowering therapy with drug treatment,
giving preference to statins.
● If baseline LDL-C is greater than or equal to 100 mg per dL, LDL-
lowering drug therapy§ should be initiated.
I (A) Modified recommendation
(changed text)
● If on-treatment LDL-C is greater than or equal to 100 mg per dL,
intensifying LDL-lowering drug therapy (may require LDL-lowering
drug combination) is recommended.
I (A) Modified recommendation
(changed text)
● If baseline LDL-C is 70 to 100 mg per dL, it is reasonable to treat
to LDL-C less than 70 mg per dL.
IIa (B) New recommendation
f triglycerides are greater than or equal to
150 mg/dL or HDL-C is less than 40 mg/
dL, emphasize weight management and
physical activity. Advise smoking cessation.
● If triglycerides are greater than or equal to 150 mg per dL or
HDL-C is less than 40 mg per dL, weight management, physical
activity, and smoking cessation should be emphasized.
I (B) Modified recommendation
(changed text)
f triglycerides are 200 to 499 mg/dL after
LDL-C–lowering therapy¶, consider adding
fibrate or niacin.**
● If triglycerides are 200 to 499 mg per dL,†† non–HDL-C target
should be less than 130 mg per dL.
I (B) Modified recommendation
(changed text)
● If triglycerides are 200 to 499 mg per dL,†† further reduction of
non–HDL-C to less than 100 mg per dL is reasonable.
IIa (B) New recommendation
6. Therapeutic options to reduce non–HDL-C include:
● More intense LDL-C–lowering therapy is indicated. I (B) New recommendation
● Niacin** (after LDL-C–lowering therapy) can be beneficial. IIa (B) Modified recommendation
(changed text)
● Fibrate therapy‡‡ (after LDL-C–lowering therapy) can be
beneficial.
IIa (B) Modified recommendation
(changed text)
f triglycerides are greater than or equal to
500 mg/dL:**‡‡
onsider fibrate or niacin‡‡ before LDL-C–
lowering therapy.**‡‡
onsider omega-3 fatty acids as adjunct for
high triglycerides. (See Section 7.12.2 in
the 2004 STEMI Guideline.)
7. If triglycerides are greater than or equal to 500 mg per dL,††§§
therapeutic options indicated and useful to prevent pancreatitis
are fibrate‡‡ or niacin** before LDL-lowering therapy; and treat
LDL-C to goal after triglyceride-lowering therapy. Achieving non–
HDL-C less than 130 mg per dL is recommended.
I (C) Modified recommendation
(changed text)
Physical Activity
Goal: 30 minutes, 7 days per week (minimum 5 days per week)
ardiac rehabilitation programs are
recommended for patients with STEMI,
particularly those with multiple modifiable
risk factors and/or those moderate- to
high-risk patients in whom supervised
exercise training is warranted. (See
Sections 7.12.12 and 8.2 in the 2004
STEMI Guideline.)
1. Advising medically supervised programs (cardiac rehabilitation)
for high-risk patients (e.g., recent acute coronary syndrome or
revascularization, HF) is recommended.
I (B) Modified recommendation
(changed text)
ssess risk, preferably with exercise test, to
guide prescription.
2. For all patients, it is recommended that risk be assessed with a
physical activity history and/or an exercise test to guide
prescription.
I (B) Modified recommendation
(changed text)
ncourage minimum of 30 to 60 min of
activity, preferably daily but at least 3 or 4
times weekly (walking, jogging, cycling, or
other aerobic activity) supplemented by an
increase in daily lifestyle activities (e.g.,
walking breaks at work, gardening,
household work).
3. For all patients, encouraging 30 to 60 minutes of moderate-
intensity aerobic activity is recommended, such as brisk walking
on most—preferably all—days of the week, supplemented by an
increase in daily lifestyle activities (e.g., walking breaks at work,
gardening, and household work).
I (B) Modified recommendation
(changed text)
4. Encouraging resistance training 2 days per week may be
reasonable.
IIb (C) New recommendation
Weight Management
Goal: BMI: 18.5 to 24.9 kg/m2
Waist circumference: Men less than 40 inches (102 cm), women less than 35 inches (89 cm)
alculate BMI and measure waist
circumference as part of evaluation.
Monitor response of BMI and waist
circumference to therapy.
1. It is useful to assess BMI and/or waist circumference on each visit
and consistently encourage weight maintenance/reduction
through an appropriate balance of physical activity, caloric intake,
and formal behavioral programs when indicated to
maintain/achieve a BMI between 18.5 and 24.9 kg/m2.
I (B) Modified recommendation
(changed text)
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tart weight management and physical
activity as appropriate. Desirable BMI
range is 18.5 to 24.9 kg/m2.
2. The initial goal of weight loss therapy should be to reduce body
weight by approximately 10% from baseline. With success, further
weight loss can be attempted if indicated through further
assessment.
I (B) Modified recommendation
(changed text)
f waist circumference is greater than or
equal to 35 inches in women or greater
than or equal to 40 inches in men, initiate
lifestyle changes and treatment strategies
for metabolic syndrome. (See Section
7.12.3 of STEMI 2004 Guideline.)
3. If waist circumference (measured horizontally at the iliac crest) is
35 inches (89 cm) or greater in women and 40 inches (102 cm)
or greater in men, it is useful to initiate lifestyle changes and
consider treatment strategies for metabolic syndrome as
indicated.
I (B) Modified recommendation
(changed text)
Diabetes Management
Goal: HbA1c less than 7%
ppropriate hypoglycemic therapy to achieve
near-normal fasting plasma glucose, as
indicated by HbA1c.
1. It is recommended to initiate lifestyle and pharmacotherapy to
achieve near-normal HbA1c.
I (B) Modified recommendation
(changed text)
reatment of other risk factors (e.g., physical
activity, weight management, blood
pressure, and cholesterol management).
(See Section 7.12.9 in the 2004 STEMI
Guideline.)
2. Beginning vigorous modification of other risk factors (e.g., physical
activity, weight management, blood pressure control, and
cholesterol management as recommended above) is beneficial.
I (B) Modified recommendation
(changed text)
3. Coordination of diabetic care with the patient’s primary care
physician or endocrinologist is beneficial.
I (C) New recommendation
Antiplatelet Agents/Anticoagulants: Aspirin
tart and continue indefinitely aspirin 75 to
162 mg/d if not contraindicated.
1. For all post-PCI STEMI stented patients without aspirin
resistance, allergy, or increased risk of bleeding, aspirin 162
mg to 325 mg daily should be given for at least 1 month after
BMS implantation, 3 months after sirolimus-eluting stent
implantation, and 6 months after paclitaxel-eluting stent
implantation, after which long-term aspirin use should be
continued indefinitely at a dose of 75 mg to 162 mg daily.
I (B) Modified recommendation
(changed text)
2. In patients for whom the physician is concerned about risk of
bleeding lower-dose 75 mg to 162 mg of aspirin is reasonable
during the initial period after stent implantation.
IIa (C) New recommendation
Antiplatelet Agents/Anticoagulants: Clopidogrel
onsider clopidogrel 75 mg/d or warfarin if
aspirin is contraindicated.
1. For all post-PCI patients who receive a DES, clopidogrel 75 mg
daily should be given for at least 12 months if patients are not
at high risk of bleeding. For post-PCI patients receiving a BMS,
clopidogrel should be given for a minimum of 1 month and
ideally up to 12 months (unless the patient is at increased risk
of bleeding; then it should be given for a minimum of 2 weeks).
I (B) Modified recommendation
(changed text)
2. For all STEMI patients not undergoing stenting (medical
therapy alone or PTCA without stenting), treatment with
clopidogrel should continue for at least 14 days.
I (B) New recommendation
3. Long-term maintenance therapy (e.g., 1 year) with clopidogrel
(75 mg per day orally) is reasonable in STEMI patients
regardless of whether they undergo reperfusion with fibrinolytic
therapy or do not receive reperfusion therapy.
IIa (C) New recommendation
Antiplatelet Agents/Anticoagulants: Warfarin
anage warfarin to INR 2.5 to 3.5 in post-STEMI
patients when clinically indicated or for those
not able to take aspirin or clopidogrel. (See
Sections 7.12.5 and 7.12.11 and Figure 37 in
the 2004 STEMI Guideline for further details of
antiplatelet and anticoagulant therapy at
hospital discharge.)
1. Managing warfarin to an INR equal to 2.0 to 3.0 for paroxysmal or
chronic atrial fibrillation or flutter is recommended, and in post-MI
patients when clinically indicated (e.g., atrial fibrillation, left
ventricular thrombus).
I (A) Modified recommendation
(changed text)
2. Use of warfarin in conjunction with aspirin and/or clopidogrel is
associated with an increased risk of bleeding and should be
monitored closely.
I (B) New recommendation
TA
A
A
S
R
G
t
T
m
t
5
t
p
s
a
f
i
236 Antman et al. JACC Vol. 51, No. 2, 2008
STEMI Focused Update January 15, 2008:210–47able 14. Continued
2004 STEMI Recommendations 2007 STEMI Recommendations
2007 COR
and LOE Comments
3. In patients requiring warfarin, clopidogrel, and aspirin therapy,
an INR of 2.0 to 2.5 is recommended with low dose aspirin
(75 mg to 81 mg) and a 75 mg dose of clopidogrel.
I (C) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: ACE Inhibitors
CE inhibitors in all patients indefinitely; start
early in stable high-risk patients (anterior
MI, previous MI, Killip class greater than or
equal to II [S3 gallop, rales, radiographic
CHF], LVEF less than 0.40).
1. ACE inhibitors should be started and continued indefinitely in all
patients recovering from STEMI with LVEF less than or equal to
40% and for those with hypertension, diabetes, or chronic kidney
disease, unless contraindicated.
I (A) Modified recommendation
(changed text)
2. ACE inhibitors should be started and continued indefinitely in
patients recovering from STEMI who are not lower risk (lower risk
defined as those with normal LVEF in whom cardiovascular risk
factors are well controlled and revascularization has been
performed), unless contraindicated.
I (B) New recommendation
3. Among lower risk patients recovering from STEMI (i.e., those with
normal LVEF in whom cardiovascular risk factors are well
controlled and revascularization has been performed) use of ACE
inhibitors is reasonable.
IIa (B) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: Angiotensin Receptor Blockers
ngiotensin receptor blockers in patients who
are intolerant of ACE inhibitors and with
either clinical or radiological signs of heart
failure or LVEF less than 0.40.
1. Use of angiotensin receptor blockers is recommended in patients
who are intolerant of ACE inhibitors and have HF or have had an
MI with LVEF less than or equal to 40%.
I (A) Modified recommendation
(changed text)
2. It is beneficial to use angiotensin receptor blocker therapy in
other patients who are ACE-inhibitor intolerant and have
hypertension.
I (B) New recommendation
3. Considering use in combination with ACE inhibitors in systolic
dysfunction HF may be reasonable.
IIb (B) New recommendation
Renin-Angiotensin-Aldosterone System Blockers: Aldosterone Blockade
ldosterone blockade in patients without
significant renal dysfunction or
hyperkalemia¶¶ who are already receiving
therapeutic doses of an ACE inhibitor, have
an LVEF less than or equal to 0.40, and have
either diabetes or heart failure. (See Section
7.12.6 in the 2004 STEMI Guideline.)
1. Use of aldosterone blockade in post-MI patients without
significant renal dysfunction or hyperkalemia¶¶ is
recommended in patients who are already receiving therapeutic
doses of an ACE inhibitor and beta blocker, have an LVEF of less
than or equal to 40%, and have either diabetes or HF.
I (A) Modified recommendation
(changed text)
Beta Blockers
tart in all patients. Continue indefinitely.
Observe usual contraindications. (See
Section 7.12.7 in the 2004 STEMI
Guideline.)
1. It is beneficial to start and continue beta-blocker therapy
indefinitely in all patients who have had MI, acute coronary
syndrome, or LV dysfunction with or without HF symptoms, unless
contraindicated.
I (A) Modified recommendation
(changed text)
Influenza Vaccination
1. Patients with cardiovascular disease should have an annual
influenza vaccination.
I (B) New recommendation
ecommendations in bold type are those the writing committee felt deserved extra emphasis. The 2007 STEMI recommendations are written in complete sentences, in accordance with ACC/AHA
uidelines methodology. “No content change” indicates the updated recommendation now includes an LOE and COR and a verb consistent with that LOE and COR as outlined in the ACC/AHA LOE/COR
able (Table 1). *For compelling indications for individual drug classes in specific vascular diseases, see the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and
reatment of High Blood Pressure (JNC 7) (87a). †Non–HDL-C indicates total cholesterol minus HDL-C. ‡Pregnant and lactating women should limit their intake of fish to minimize exposure to
ethylmercury. §When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C less than 70 mg per dL is the chosen target, consider drug titration to achieve
his level to minimize side effects and cost. When LDL-C less than 70 mg per dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of greater than
0% in LDL-C levels by either statins or LDL-C–lowering drug combinations. Standard dose of statin with ezetimibe, bile acid sequestrant, or niacin. ¶Treat to a goal of non–HDL-C substantially less
han 130 mg per dL. **Dietary supplement niacin must not be used as a substitute for prescription niacin. ††The use of resin is relatively contraindicated when triglycerides are greater than 200 mg
er dL. ‡‡The combination of high-dose statin plus fibrate can increase risk for severe myopathy. Statin doses should be kept relatively low with this combination. §§Patients with very high triglycerides
hould not consume alcohol. The use of bile acid sequestrant is relatively contraindicated when triglycerides are greater than 200 mg per dL. Creatinine should be less than 2.5 mg per dL in men
nd less than 2.0 mg per dL in women. ¶¶Potassium should be less than 5.0 mEq/L.
ACE indicates angiotensin-converting enzyme; BMI, body mass index; CHF, congestive heart failure; COR, classification of recommendation; HDL-C, high-density lipoprotein cholesterol; HF, heartailure; INR, international normalized ratio; LDL-C, low-density lipoprotein cholesterol; LOE, level of evidence; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary
ntervention; and STEMI, ST-elevation myocardial infarction.
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